

INFORMATION DOCUMENT

Scope Fluidics

Joint-Stock Company

with its principal place of business in Warsaw

prepared for the purpose of admission to trading on the NewConnect market

operated as an alternative trading system

by the Warsaw Stock Exchange S.A.

231,540 Series F Shares

This Information Document has been prepared in connection with the application for the introduction of the financial instruments covered by this document to trading in the alternative trading system operated by the Warsaw Stock Exchange (Giełda Papierów Wartościowych w Warszawie S.A.)

The introduction of the financial instruments to trading in the alternative trading system does not constitute admission or introduction of those instruments to trading on the regulated market operated by the Warsaw Stock Exchange (on the main or parallel market).

Investors should be aware of risks involved in investing in financial instruments listed in an alternative trading system and their investment decisions should be preceded by an appropriate analysis and, if appropriate, by consultation with an investment adviser.

The contents of this Information Document have not been approved by the Warsaw Stock Exchange with respect to the compliance of the information contained therein with the factual state or legal regulations.

Authorised Adviser

Mercurius

Financial Advisors

Mercurius Financial Advisors Spółka z ograniczoną odpowiedzialnością Sp.k.

Warsaw, 12 May 2020.

Statements by the persons responsible for the information contained in the Information Document

1. Issuer

Name (business name): Scope Fluidics Spółka Akcyjna
Principle place of business: Warsaw
Address: ul. Duchnicka 3, bud. 16, wejście A, 01-796 Warsaw
Telephone numbers: +48 22 343-30-72
Email: biuro@scopefluidics.com
Website: www.scopefluidics.com

The following individuals act on behalf of the Issuer:

- **Piotr Garstecki** - President of the Management Board
- **Marcin Izydorzak** - Member of the Management Board
- **Szymon Ruta** - Member of the Management Board

Statement by persons acting on behalf of the Issuer

Acting on behalf of Scope Fluidics with its principal place of business in Warsaw, we represent that, to the best of our knowledge and having taken all reasonable care to ensure that such is the case, the information contained in this Information Document is true, accurate and consistent with the facts and that it does not omit any facts that could affect its sense and valuation of financial instruments introduced to trading, and that the Information Document presents fairly risk factors related to participation in trading in these instruments.

Piotr Garstecki

President Of The Management Board

Marcin Izydorzak

Member Of The Management Board

Szymon Ruta

Member of the Management Board

2. Authorised Advisor

Name (business name): Mercurius Financial Advisors Spółka z ograniczoną odpowiedzialnością spółka komandytowa

Principle place of business: Warsaw

Address: ul. Śmiała 26, 01-523 Warsaw

Telephone numbers: +48 22 327-16-70, fax +48 22,327 16 71

Email: mfa@mfa.pl

Website: www.mfa.pl

The following persons act on behalf of the Authorised Advisor:

- **Michał Kowalczewski** - President of the Management Board
- **Robert Drażykowski** - Member of the Management Board

Statement by the Authorised Adviser

Acting on behalf of Mercurius Financial Advisors Spółka z ograniczoną odpowiedzialnością sp.k. we represent that this Information Document has been prepared in accordance with the requirements specified in Annex No 1 to the Alternative Trading System Rules adopted as Resolution No 147/2007 of the Management Board of the Warsaw Stock Exchange of 1 March 2007 (as amended), and that according to our best knowledge and in accordance with the documents and information provided by the Issuer, the information contained in the Information Document is true, accurate and complies with the facts and that no facts were omitted that could affect its sense and valuation of financial instruments introduced to trading, and that the Information Document presents fairly risk factors related to participation in trading in these instruments.

Michał Kowalczewski

President Of The Management Board

Robert Drażykowski

Member Of The Management Board

Table of Contents

Statements by the persons responsible for the information contained in the Information Document..... 2

1. Issuer.....2

2. Authorised Advisor.....3

Table of Contents.....4

1. Information about the Issuer.....6

2A. Information as to whether the issuer's activities are subject to an authorisation, licence or approval, and if so, the subject matter and number of the authorisation, licence or approval, stating the authority which granted them.....6

3. Number, type, unit nominal value and identification of issues of financial instruments to be introduced to trading in the alternative system.....6

4. Information on subscriptions or sales of financial instruments that are the subject of the application for introduction, taking place in the last 12 months preceding the date of filing the application for introduction - to the extent specified in § 4 Section 1 of Exhibit 3 to the ATS Rules.....7

4A. Information on whether the Issuer, by making a non-public offering of the shares referred to in the application in connection with the intention to introduce them to the alternative trading system, has fulfilled the requirements referred to in § 15c of the ATS Rules.....8

5. The legal basis for the issue of the financial instruments, indicating the body or persons authorised to take the decision to issue the financial instruments, and the date and form of the decision to issue the financial instruments, citing its content.....8

5a. Indication whether the shares have been subscribed for in cash, against cash payments or against contributions in kind, with a brief description of how they were subscribed for.....19

6. Indication of the dates from which the shares participate in the dividend.....19

7. A summary of the rights and obligations arising from the financial instruments, the envisaged additional benefits for the Issuer incumbent on the acquirer, as well as the obligations provided for in the Articles of Association or in legal regulations for the acquirer or transferor to obtain appropriate permits or to make certain notifications.....19

8. Indication of the persons managing and supervising the Issuer, the Authorised Advisor, and the entities auditing the Issuer's financial statements (with indication of the auditors carrying out the audit).....23

9. Basic information on the Issuer's capital links which have a significant impact on its activities, with an indication of significant entities of its capital group, including in relation to each of them at least the name, legal form, principal place of business, object of activity and the Issuer's share in the share capital and the total number of votes.....23

10. Basic information on personal, material and organisational relationships.....24

11. Key risk factors relating to the Issuer and the financial instruments being introduced.....24

12. Data on the Issuer.....31

13. Additional information, including the amount of share capital and indication of the Issuer's corporate documents available for inspection.....37

13a. The Issuer's statement to the effect that it believes that the level of working capital is sufficient to meet its needs for the period of 12 months from the date of preparation of the information document and, if not, a proposal for the provision of additional working capital. 38

13b. Information on projected changes in the share capital as a result of bondholders exercising their rights under convertible bonds or bonds giving priority to new issues of shares in the future, or as a result of exercising their rights by holders of subscription warrants, with an indication of the value of the projected conditional share capital increase and the date of expiry of the rights of the entities authorised to acquire those shares.....38

13c. Indication of the number of shares and the value of the share capital by which, pursuant to the Articles of Association providing for the authorisation of the Management Board to increase the share capital within the limits of the authorised capital, the share capital may be increased, as well as the number of shares and the value of the share capital by which the share capital may still be increased under this procedure.....38

14. Indication of the place of access.....39

Appendices.....40

Appendix 1 - Current extract from the National Court Register (KRS).....40

Appendix 2 - Articles of Association.....48

Appendix 3 - Definitions and explanations of abbreviations.....60

1. Information about the Issuer

Name (business name), legal form: Scope Fluidics Spółka Akcyjna
Principle place of business: Warsaw, Poland
Address: ul. Duchnicka 3, bud. 16, entrance A 01-796 Warsaw
Telephone numbers: +48 22 343-30-72
Email: biuro@scopefluidics.com
Website: www.scopefluidics.com
REGON Statistical Identification Number: 14275417000000
NIP Tax Identification Number: 5272645989
KRS Number: 0000668408

2A. Information as to whether the issuer's activities are subject to an authorisation, licence or approval, and if so, the subject matter and number of the authorisation, licence or approval, stating the authority which granted them

The activities carried out by the Issuer do not require permits, licences or approvals.

3. Number, type, unit nominal value and identification of the issues of the financial instruments to be introduced to trading in the alternative system

This Information Document has been prepared in relation to the intention of introducing to the alternative trading system on the NewConnect market run by the Warsaw Stock Exchange S.A. 231,540 (two hundred and thirty one thousand five hundred and forty) ordinary series F bearer shares with a nominal value of PLN 0.10 (ten grosz) each.

On 13 November 2019, the Issuer entered into a conditional agreement with TOTAL FIZ obliging it to subscribe for shares under the Issuer's share capital increase. Under this agreement, the Issuer agreed to offer TOTAL FIZ to take up, and TOTAL FIZ agreed to take up, up to 231,540 (two hundred and thirty-one thousand five hundred and forty) series F ordinary bearer shares with a nominal value of PLN 0.10 each in return for a cash contribution. Prior to acquiring new shares of the Issuer, TOTAL FIZ intended to carry out an accelerated book-building process and sell part of its holding in the Issuer (up to 170,772 shares of the Issuer). TOTAL FIZ intended to carry out those actions in such a way that TOTAL FIZ's shareholding in the Issuer's share capital before and after such actions would be at least equal (i.e. 26.25%).

On 10 December 2019, the process of building an accelerated bookbuild (ABB) by a shareholder of the Company was commenced and completed. Under the ABB, the sale price per Company share was set at PLN 60 and the number of Company shares sold by the Shareholder was set at 170,772, representing approximately 7.37% in the Company's share capital, and approximately 7.37% of the total number of votes at the Company's General Meeting.

On 13 December 2019, the Issuer entered into an agreement with TOTAL FIZ for the private placement of 231,540 series F shares at an issue price of PLN 60 per share, in connection with the offer to TOTAL FIZ to acquire 231,540 series F shares with a nominal value of PLN 0.10 (ten groszy) each in the Issuer's increased share capital.

Series F shares introduced to trading in the alternative trading system represent 10% (ten percent) of all shares issued by the Issuer. The total nominal value of the financial instruments introduced to trading in the ATS on the basis of this Information Document is PLN 23,154.00 (twenty-three thousand one hundred fifty-four zloty).

4. Information on subscriptions or sales of the financial instruments that are the subject of this application for introduction, taking place in the last 12 months preceding the date of filing the application for introduction - to the extent specified in § 4 Section 1 of Appendix 3 to the ATS Rules

Detailed information to the extent specified in § 4 Section 1 of Appendix 3 to the ATS Rules is set out below.

1. Subscription start and end date:

The subscription started and ended on 13 December 2019, i.e. on the date on which all the offered F shares were taken up by TOTAL FIZ.

2. Date of allotment of shares:

In a private placement, shares are not allotted and investors do not subscribe but enter into agreements to subscribe for shares. Under the completed private subscription:

- a) all F shares were offered,
- b) the offer was addressed to individually designated addressee TOTAL FIZ,
- c) TOTAL FIZ subscribed for all F shares offered in the private placement on 13 December 2019.

3. Number of shares subscribed for:

The private subscription comprised 231,540 Series F ordinary bearer shares with a nominal value of PLN 0.10 (ten grosz) each.

4. The rate of reduction in individual tranches in the event that in at least one tranche the number of shares allocated was smaller than the number of shares subscribed for:

Not applicable - the private placement was not divided into tranches and there was no reduction.

5. Number of shares allotted in the subscription:

As part of the private subscription, 231,540 Series F ordinary bearer shares with a nominal value of 10 gr (ten groszy) each were taken up.

6. The price at which the shares were taken up:

The issue price per share was PLN 60.00. The total issue price for all series F shares was PLN 13,892,400. The price for the series F shares was paid in cash to the Issuer's bank account.

6a. Information on how the subscribed shares were paid for:

The required cash contribution for all F shares was made by TOTAL FIZ on 13 December 2019.

7. The number of persons who subscribed for the subscribed shares in each tranche:

The series F shares were offered by private placement exclusively to TOTAL FIZ, with whom an agreement to take up the shares had been made.

8. The number of persons to whom shares were allocated under the subscription carried out in each tranche:

The share subscription agreement was made with one entity, i.e. TOTAL FIZ.

9. Name(s) of underwriters who have taken up shares in the performance of underwriting agreements, stating the number of shares they have taken up together with the actual price of the shares (issue or sale price, after deduction of the consideration for taking up the shares, in the performance of the underwriting agreement, acquired by the underwriter):

The series F shares were not subscribed for by underwriters. No underwriting agreement has been entered into.

10. A total determination of the amount of the costs which have been included in the issue costs with an indication of the amount of costs by title, broken down at least into costs:

- a) Preparation and conduct of the offer: PLN 179,400.00;
- b) Remuneration of the underwriters, separately for each of them: PLN 0.00;

- c) Preparation of a public information document or an information document, including costs of advisory services: PLN 25,000.00,
d) Offer promotion: PLN 0.00

The method of settlement of the costs referred to in item 10 in the accounting books and the method of their recognition in the Issuer's financial statements - in accordance with Article 36 (1) (2b) of the Accounting Act.

4A. Information on whether the Issuer, by making a non-public offering of the shares referred to in the application in connection with the intention to introduce them to the alternative trading system, has fulfilled the requirements referred to in § 15c of the ATS Rules

The Issuer has fulfilled the requirements referred to in § 15c of the ATS Rules.

5. The legal basis for the issue of the financial instruments, stating the authority or persons authorised to take the decision to issue the financial instruments, and the date and form of the decision to issue the financial instruments, citing its contents

5.1. Authority authorised to take the decision to issue financial instruments

The body authorised to decide on the issue of the Issuer's financial instruments is the General Meeting, in accordance with the provisions of Article 431 of the Polish Companies Act (KSH).

5.2. Date and form of the decision to issue the financial instruments and citation of its content

Pursuant to Article 431 § 1 of the Polish Companies Act, in conjunction with Article 430 of the Polish Companies Act, an increase in share capital requires a resolution of the General Shareholders' Meeting. In order to be effective, such a resolution should be adopted by a majority of three-quarters of the votes cast, in line with Article 415 (1) of the Polish Companies Act, however in the interest of the company, the General Meeting may, under Article 433 § 2 of the Polish Companies Act, divest shareholders of the preemptive right in part or in whole. In such a case, a resolution of the General Shareholders Meeting on the exclusion of the preemptive right requires a majority of at least four fifths of the votes cast. A resolution on share capital increase may not be submitted to the Registry Court after the lapse of six months from the date of its adoption. Pursuant to Article 310 (2) of the Polish Companies Act, a resolution of the General Shareholders Meeting may stipulate the minimum or maximum amount by which the share capital is to be increased. In such an event, the share capital increase comes into effect upon subscription by the shareholders of such a number of shares whose aggregate nominal value is at least equal to the minimum amount of the share capital stipulated in the resolution on the increase - and - upon submission by the Management Board of a declaration on the amount of the subscribed share capital in the form of a notarial deed. The amount of the subscribed capital should be within the limits specified in the resolution of the general meeting. An increase of the share capital takes place upon entry of amendments to the company's Articles of Association in the National Court Register.

- Series F Shares

The series F shares were issued on the basis of Resolution No. 3 of the Issuer's Extraordinary General Meeting on increasing the Company's share capital through the issuance of series F shares by way of private subscription with complete exclusion of the preemptive rights of the existing shareholders, dematerialisation and introduction to trading in the Alternative Trading System on the NewConnect market operated by the Warsaw Stock Exchange, and amendment to the Articles of Association of 10 December 2019. This resolution was drawn up in the form of a notarial deed by Daniel Nestorowicz, civil-law notary based in Warsaw (Roll of Deeds A No. 303/2019). The content of this resolution is set out below:

**"RESOLUTION NO. 3
Extraordinary General Meeting of Scope Fluidics S.A.
of 10 December 2019**

concerning: the increase of the Company's share capital through the issuance of series F shares by way of private subscription with complete exclusion of the preemptive right of the existing shareholders, dematerialisation and introduction to trading in the Alternative Trading System on the NewConnect market operated by the Warsaw Stock Exchange ("WSE"), and amendment of the Articles of Association.

§1

Acting pursuant to Article 431 § 1, § 2 (1), § 7 in conjunction with art. 310 § 2, Article 432 § 1 and Article 433 § 2 of the Polish Companies Act, the Company's Extraordinary General Meeting adopts the following resolution:

1) the Company's share capital shall be increased from PLN 231,540 (two hundred and thirty-one thousand five hundred and forty zloty) by an amount of no less than PLN 0.1 (ten grosz) and no more than PLN 23,154 (twenty-three thousand one hundred and fifty-four zloty), i.e. to an amount of no less than PLN 231,540.10 (two hundred and thirty-one thousand five hundred and forty zloty and ten grosz), and no more than PLN 254,694 (two hundred and fifty-four thousand six hundred and ninety-four zloty),

2) the increase of the Company's share capital referred to in section 1 above shall be effected through the issuance of no less than 1 (one) share and no more than 231,540 (two hundred and thirty-one thousand five hundred and forty) ordinary series F bearer shares with a nominal value of PLN 0.1 each (hereinafter referred to as "series F shares"),

3) the Company's Management Board shall be authorised to set the final terms of the offer to take up F shares, including determination of the issue price of F shares,

4) the F shares shall participate in the dividend, on an equal basis with the other shares, as follows:

a. starting from the dividend relating to the profit for the financial year 2019 - if the recording of the F shares in the securities accounts takes place at the latest on the dividend date set by the Ordinary General Meeting in the resolution on the distribution of profit for the financial year 2019,

b. starting from the dividend relating to the profit for the financial year 2020 - if the recording of the F shares in the securities accounts takes place after the dividend date set by the Ordinary General Meeting in the resolution on the distribution of profit for the financial year 2019,

5) the series F shares shall be covered exclusively by cash contributions prior to the registration of the share capital increase through the issuance of series F shares,

6) the issuance of series F shares shall be carried out by way of private subscription referred to in Article 431 § 2 (1) of the Polish Commercial Companies Code;

7) it is agreed that the subscription for the Company's F shares under the issuance referred to above shall be made by way of an offer made by the Company and accepted by the designated addressee, i.e. TOTAL Fundusz Inwestycyjny Zamknięty, with its principal place of business in Warsaw, or its subsidiary;

8) the series F shares shall be the subject of application for introduction to trading in the Alternative Trading System on the NewConnect market operated by the WSE,

9) in connection with the application for admission of the series F shares to trading in the Alternative Trading System on the NewConnect market operated by the WSE, the Management Board decided that the series F shares shall be dematerialised within the meaning of Article 5 (1) of the Act on Trading in Financial Instruments of 29 July 2005.

§ 2

In the interest of the Company, the preemptive rights of the existing shareholders to subscribe for all the shares of the new issuance of series F are entirely waived. The opinion of the Management Board regarding the divestment of the preemptive rights to F shares, presented in writing to the General Meeting, is acknowledged. The written opinion of the Management Board justifying the divestment of the shareholders' preemptive rights to F shares and the manner of determining the issue price of those shares has been presented to the General Meeting and constitutes an appendix to this notarial deed.

§ 3

The Management Board of the Company is authorised and obliged to perform all legal and factual acts aimed at the implementation of this resolution, in particular:

1. to determine the final terms of the offer for F shares to be taken up, including determining of the issue price of F shares;
2. to make an offer for F shares to be subscribed for on the terms provided for in this resolution;
3. to determine the contents of the agreement on F shares subscription and enter into the agreement on F shares subscription;
4. to submit, pursuant to Article 310 § 2 of the Polish Commercial Companies Code, prior to the submission of the application for registration of the capital increase, a declaration in the form of a notarial deed on the amount of the subscribed capital;
5. take steps with a view to:
 - a) registering in the National Court Register the increase of the share capital through the issuance of series F shares and the amendment of the Company's Articles of Association related to the increase of the share capital;
 - b) dematerialisation of F shares and entering into an agreement with the National Depository for Securities (Krajowy Depozyt Papierów Wartościowych S.A.) on registration of the securities at the depository, as referred to in Article 5 of the Act on Trading in Financial Instruments;
 - c) introducing F shares to trading in the Alternative Trading System on the NewConnect market operated by the WSE;
6. perform all other acts in connection with the implementation of the provisions of this resolution.

§ 4

In connection with the increase of the share capital through the issuance of the series F shares, the Company's Extraordinary General Meeting, acting pursuant to Article 430 of the Commercial Companies Code, resolves to amend § 4 sections 1 and 2 of the Company's Articles of Association, giving it the following wording:

1. The Company's share capital shall be no less than PLN 231,540.10 (two hundred and thirty-one thousand five hundred and forty zloty and ten grosz) and no more than PLN 254,694 (two hundred and fifty-four thousand six hundred and ninety-four zloty) and shall be divided into no fewer than 2,315,401 (two million three hundred and fifteen thousand and four hundred and one) shares and no more than 2,546,940 (two million five hundred and forty six thousand nine hundred and forty) shares, with a nominal value of PLN 0.1 (ten grosz) per share.

2. The share capital shall be composed of:

1) Series A registered shares in the number of 101,107 (one hundred and one thousand one hundred and seven) numbered 1213286 to 1314392 with the total value of PLN 10,110.70 (ten thousand one hundred and ten zloty and seventy grosz).

2) Series B bearer shares in the number of 1,268,893 (one million two hundred sixty-eight thousand eight hundred ninety-three) numbered from 0000001 to 1268893 with the total value of PLN 126,889.30 (one hundred twenty-six thousand eight hundred eighty-nine thirty zlotys).

3) 900,000 (nine hundred thousand) series C ordinary bearer shares with consecutive numbers from 000001 to 900000.

4) 34,050 (thirty-four thousand and fifty) series D ordinary registered shares with consecutive numbers from 00001 to 34050.

5) 11,350 (eleven thousand three hundred and fifty) series E ordinary registered shares with consecutive numbers from 00001 to 11350.

6) not fewer than 1 (one) share and no more than 231,540 (two hundred thirty one thousand five hundred forty) series F ordinary bearer shares with consecutive numbers from 000001 and up to no more than 231,540."

§ 5

The resolution shall come into force as of the date of its adoption, with the reservation that the increase of the share capital and the amendment of the Company's Articles of Association shall take place as of the date of the entry of the amendment in the National Court Register."

The President stated that:

- an open ballot saw 1,460,138 valid votes cast out of 1,460,138 shares, representing 63.06 % of the share capital, including 1,460,138 votes 'in favour', 0 votes 'against' and 0 abstentions,
- there were no objections to the resolution,
- **the resolution was adopted.**

On 13 December 2019, the Management Board adopted a resolution to determine the issue price for the Company's newly issued series F shares. The Management Board set the issue price for series F shares at PLN 60.00 (sixty zloty) per one series F share.

Due to the fact that the share capital increase implemented pursuant to Resolution No. 3 of the Extraordinary General Meeting of 10 December 2019 fell within its statutory differentials, the Issuer's Management Board, on 16 December 2019, acting pursuant to Article 431 § 7 in connection with Article 310 § 2 and 4 of the Commercial Companies Code, issued a statement on the specification of the share capital in the Issuer's Articles of Association. The contents of this statement are set out below:

CIVIL-LAW NOTARY OFFICE
DANIEL NESTOROWJCZ
EWA SZMAGALSKA
SPÓŁKA CYWILNA
ul. Ogrodowa 4 Apartment 3 ,00-896 Warszawa
NIP 5272910859 REGON 384775278
Tel.: 888-67-88-77
nestorowicz@ notariusze.waw.pl
szmagalska@notariusze.waw.pl

Roll of Deeds A No 334/2019

NOTARIAL DEED

On the sixteenth day of December in the year two thousand and nineteen (16.12.2019), before me, Ewa Szmagalska, civil-law notary based in Warsaw running her civil-law notary's office at Ogrodowa Street No. 4 Apartment 3, arrived at building No. 16 at Duchnicka Street No. 3 in Warsaw, the following persons appeared:

1. **Piotr Garstecki**, son of Kazimierz and Maria, with his PESEL Identity Number: 75100800830, holder of the Personal Identity Card ATM 665952, valid until 15 March 2021, residing at the following address: 01-492 Warsaw, Obrońców Tobruku street 23 Apartment 61,
2. **Marcin Izydorzak**, son of Kazimierz and Czesława, with his PESEL Identity Number: 74042500633, holder of the Personal Identity Card ATM 395353, valid until 13 July 2022, residing at the following address: 01-492 Warsaw, Obrońców Tobruku street 30 Apartment 15,
3. **Szymon Michał Ruta**, son of Sławomir and Maria, with his PESEL Identity Number: 75112801939, holder of the Personal Identity Card ATM 616740, valid until 23 March 2028, residing at the following address: 03-140 Warsaw, Odkryta street 36A Apartment 110, acting on this deed as all members of the three-person Management Board of the company under the business name: **SCOPE FLUIDICS Spółka Akcyjna** with its principal place of business in Warsaw (company address: 01-796 Warsaw, ul. Duchnicka 3, building 16, entrance A, REGON: 142754170, NIP: 5272645989), entered in the Register of Entrepreneurs of the National Court Register kept by the District Court for the Capital City of Warsaw in Warsaw, XII Business Division of the National Court Register under KRS number 0000668408 ("**the Company**"),

being, according to the information presented for the purpose of this deed, equivalent to the current copy of the entry in the Register of Entrepreneurs collected for the Company pursuant to Article 4 (4aa) of the Act of 20 August 1997 on the National Court Register, as at 16 December 2019, 11:24:32 a.m., with the Appearing Parties assuring that none of them had been dismissed, limited or suspended in their functions, and the data disclosed in the contents of the excerpt from the Register of Entrepreneurs remaining valid.

The civil-law notary established the identity of the Appearing Parties on the basis of their identification documents referenced next to their names, while the other data was provided based on the Appearing Parties' statements.

The Appearing Parties declare that there are no circumstances that would oblige them to change the particulars entered in the identity documents they presented or that would constitute grounds for their annulment.

MINUTES OF THE MANAGEMENT BOARD MEETING

§ 1 The meeting of the Company's Management Board was opened by Piotr Garstecki, President of the Management Board, who was unanimously elected Chair of the meeting.

Piotr Garstecki stated that the subject of the meeting of the Management Board would be adoption of a resolution on the amount of the subscribed share capital and on specification of the amount of the share capital in the Company's Articles of Association.

Piotr Garstecki further stated that all members of the Management Board had been duly notified of the Management Board meeting and that the Management Board could therefore adopt the resolution which was the subject of this meeting.

Piotr Garstecki stated that he would put Resolution L to the vote as follows:

“RESOLUTION No 10/2019

**The Management Board of the company operating under the business name: Scope Fluidics S.A.
with its principal place of business in Warsaw
of 16 December 2019**

***on the amount of the subscribed share capital, and
further specification of the amount of the share capital in the Articles of Association***

§1

By Resolution No. 3 of the Company's Extraordinary General Meeting of 10 December 2019 on increasing the Company's share capital through the issuance of series F shares by private subscription with complete exclusion of the preemptive rights of the existing shareholders, dematerialisation, and introduction to trading in the Alternative Trading System on the NewConnect market operated by the Warsaw Stock Exchange S.A. ("WSE"), and on an amendment to the Articles of Association documented by a notarial deed comprising the Minutes of the Company's Extraordinary General Meeting, drawn up on 10 December 2019 by Daniel Nestorowicz, civil-law notary based in Warsaw (Rep. A No. 303/2019) ("**Resolution on Share Capital Increase**"), the Company's Extraordinary General Meeting resolved, acting pursuant to Article 431 § 1, § 2 (1)), § 7 in conjunction with Article 310 § 2, Article 432 § 1 and Article 433 § 2 of the Polish Commercial Companies Code, among other things, that:

- 1) the Company's share capital shall be increased from PLN 231,540 (two hundred and thirty-one thousand five hundred and forty zloty) by an amount of no less than PLN 0.1 (ten grosz) and no more than PLN 23,154 (twenty-three thousand one hundred and fifty-four zloty), i.e. to an amount of no less than PLN 231,540.10 (two hundred and thirty-one thousand five hundred

- and forty zloty and ten grosz), and no more than PLN 254,694 (two hundred and fifty-four thousand six hundred and ninety-four zloty),
- 2) the increase of the Company's share capital referred to in section 1 above shall be effected through the issuance of no fewer than 1 (one) share and no more than 231,540 (two hundred and thirty-one thousand five hundred and forty) series F ordinary bearer shares with a nominal value of PLN 0.1 each (hereinafter referred to as "series F shares"),
 - 3) the Company's Management Board shall be authorised to set the final terms of the F share subscription offer, including determination of the issue price of the F shares,
 - 4) the F shares shall participate in the dividend, on an equal basis with the other shares, as follows:
 - a. starting from the dividend relating to the profit for the financial year 2019 - if the recording of the F shares in the securities accounts takes place at the latest on the dividend date set by the Ordinary General Meeting in the resolution on the distribution of profit for the financial year 2019,
 - b. starting from the dividend relating to the profit for the financial year 2020 - if the recording of the F shares in the securities accounts takes place after the dividend date set by the Ordinary General Meeting in the resolution on the distribution of profit for the financial year 2019,
 - 5) the series F shares shall be covered exclusively by cash contributions prior to the registration of the share capital increase through the issuance of series F shares,
 - 6) the issuance of series F shares shall be carried out by way of private subscription referred to in Article 431 § 2 (1) of the Polish Commercial Companies Code;
 - 7) it is agreed that the subscription for the Company's F shares under the issuance referred to above shall be made by way of an offer made by the Company and accepted by the designated addressee, i.e, TOTAL Fundusz Inwestycyjny Zamknięty with its principal place of business in Warsaw, or its subsidiary;
 - 8) the series F shares shall be the subject of application for introduction to trading in the Alternative Trading System on the NewConnect market operated by the WSE,
 - 9) in connection with the application for admission of the series F shares to trading in the Alternative Trading System on the NewConnect market operated by the WSE, the Management Board decided that the series F shares shall be dematerialised within the meaning of Article 5 (1) of the Act on Trading in Financial Instruments of 29 July 2005.

§2

1. As a result of the private subscription of the F series shares, under the share subscription agreement with TOTAL FIZ with its principal place of business in Warsaw covering the F series shares, 231,540 F series shares with the nominal value of PLN 0.10 each, i.e. with a total nominal value of PLN 23,154.00, were effectively taken up.
2. In connection with the above, pursuant to Article 431 §7 in conjunction with Article 310 §2 of the Polish Commercial Companies Code, the Company's Management Board represents that the final amount of the subscribed increase of the Company's share capital is PLN 23,154.00.
3. The Company's share capital was increased to the amount of PLN 254,694.00, i.e. by the amount referred to in section 2 above, which is within the limits indicated in the Resolution on Share Capital Increase.

§3

Pursuant to Article 431 §7 in conjunction with Article 310 §4 of the Commercial Companies Code, the Company's Management Board hereby makes an addition to the share capital in the Company's Articles of Association, so that §4 (1) and (2) of the Company's Articles of Association shall read as follows:

1. *The Company's share capital is PLN 254,694 (two hundred and fifty-four thousand six hundred and ninety-four zloty) and is divided into 2,546,940 (two million five hundred and forty-*

six thousand nine hundred and forty) shares, with the nominal value of PLN 0.1 (ten grosz) per share.

2. The share capital shall be composed of:

- 1) Series A registered shares in the number of 101,107 (one hundred and one thousand one hundred and seven) numbered 1213286 to 1314392, with the total value of PLN 10,110.70 (ten thousand one hundred and ten zloty and seventy grosz),
- 2) Series B bearer shares in the number of 1,268,893 (one million two hundred sixty eight thousand eight hundred ninety three) numbered from 0000001 to 1268893 with the total value of PLN 126,889.30 (one hundred twenty six thousand eight hundred eighty nine zloty thirty grosz),
- 3) 900,000 (nine hundred thousand) series C ordinary bearer shares with consecutive numbers from 000001 to 900000,
- 4) 34050 (thirty-four thousand and fifty) series D ordinary registered shares with consecutive numbers from 00001 to 34050.
- 5) 11,350 (eleven thousand three hundred and fifty) series E ordinary registered shares with consecutive numbers from 00001 to 11350,
- 6) 231,540 (two hundred thirty-one thousand five hundred forty) series F ordinary shares bearer shares with consecutive numbers from 000001 to 231540.

§ 4

The resolution shall enter into force on the date of its adoption.

Piotr Garstecki stated that the above resolution was adopted unanimously by the Management Board.

Following the adoption of the above resolution, the Chairman closed the Management Board meeting.

§2 The cost of this deed shall be borne by the Company.

§3 Copies of this Deed may be issued to the Company and to the Company shareholders in any number.

§4 The fees payable are:

- the Civil-Law Notary's fee under §9 and §17 of the Ministry of Justice's Regulation of 28 June 2004 concerning maximum notary fee rates.....PLN 550.00
- 23% VAT under Article 146a (1) of the VAT Act of 11 March 2004 on tax on goods and services.....PLN 126.50

This Deed has been read out aloud, accepted and signed.

Signatures of the Appearing Parties and the Civil-Law Notary made on the original deed

Roll of Deeds A No 335/2019

The above extract has been issued to: the Company

The fees payable are:

- notarial fee PLN 24.00
- pursuant to § 12 of the Ministry of Justice Regulation of 28.06.2004 r. (Journal of Laws, 2018, Item 272)
- 23% VAT - PLN 5.52
- pursuant to the Act of 11.03.2004 (Journal of Laws, 2018, Item 2174, as amended)
Warsaw, 16 December 2019.

Ewa Szmagalska
Civil-Law Notary

On 16 December 2019, the Supervisory Board adopted a resolution to adopt the consolidated text of the Issuer's Articles of Association.

The share capital increase carried out on the basis of Resolution No. 3 of the Issuer's Extraordinary General Meeting of 10 December 2019 was registered by Court decision of 2 January 2020.

5a. An indication of whether the shares have been subscribed for in cash, against cash payments in another manner, or against contributions in kind, with a brief description of how the shares have been paid for

The series F shares were subscribed for in cash in such a way that 231,540 series F shares were subscribed for at an issue price of PLN 60.00 each, i.e. for a total issue price of PLN 13,892,400.

6. Indication of the dates from which the shares participate in the dividend

The series F shares shall participate in the dividend on an equal basis with the other shares in the share capital of Scope Fluidics, as follows:

- a) starting from the dividend relating to the profit for the 2019 financial year - if the recording of the F shares in the securities accounts takes place at the latest on the dividend date set by the Annual General Meeting of Scope Fluidics in the resolution on the distribution of profit for the 2019 financial year,
- b) starting from the dividend relating to the profit for the financial year 2020 - if the recording of the F shares in the securities accounts takes place after the dividend date set by the Annual General Meeting of Scope Fluidics in the resolution on the distribution of profit for the financial year 2019.

7.A summary of the rights and obligations arising out of the financial instruments, the envisaged additional benefits for the Issuer incumbent on the acquirer, as well as the obligations provided for in the Articles of Association or in legal regulations for the acquirer or transferor to obtain appropriate permits or to make certain notifications

7.1. Property rights vested in the Issuer's shareholders

The right to share in the annual profit, i.e. the right to dividend (Articles 347-348 CCC)

Shareholders are entitled to a share of the profit shown in the audited financial statements and allocated by the General Meeting for distribution to shareholders.

The shareholders entitled to dividends for a given financial year are those entitled to shares on the dividend date, while the ordinary general meeting determines the dividend date and the dividend payment date. Pursuant to Art. 348 § 4 of the Polish Companies Act, the dividend date may be set as a date falling no earlier than five days and no later than three months after the date of the resolution. The dividend payment date may be set within the next three months, counting from the dividend day.

A preemptive right to acquire new shares in relation to the number of shares already held, i.e. the preemptive right (Article 433 CCC)

Shareholders have a preemptive right to subscribe for new shares in proportion to the number of shares held. In the interest of the company, the General Meeting may divest shareholders of their preemptive rights in whole or in part. A resolution of the General Meeting requires a majority of at least 4/5 (four fifths) of the votes. Shareholders may be divested of their preemptive rights to shares if this has been announced in the agenda of the General Meeting.

A 4/5 majority is not required if:

- 1) the resolution on the capital increase provides that the new shares are to be subscribed for in full by a financial institution (the underwriter of the issue), with an obligation to offer them subsequently to shareholders in order to enable them to exercise their preemptive rights under the terms of the resolution,
- 2) the resolution provides that the new shares are to be subscribed for by the underwriter of the issue in the event that shareholders with preemptive rights do not take up some or all of the shares offered to them.

The right to a share in the Issuer's assets remaining after creditors have been satisfied or secured in the event of the Issuer's liquidation.

A shareholder shall have the right to participate in the distribution of the Issuer's assets in the event of dissolution or liquidation in proportion to his share in the share capital.

Right to sell the Issuer's shares

Under Article 337 § 1 CCC, the Issuer's shares are transferable. A shareholder of a public company may transfer his shares in the period between the date of registration of his participation in the General Meeting of the Issuer (record date) and the end of the General Meeting of the Issuer (Article 406⁴ CCC).

Right of pledge or usufruct on shares (Article 340 § 3 CCC)

As long as the shares in the public company on which the pledge or usufruct has been established are recorded in accounts with a brokerage house or a bank keeping securities accounts, the shareholder shall have the right to vote on those shares.

Right related to buy-back of shares

Pursuant to Article 416 § 4 and Article 417 § 4 of the Polish Companies Act, the effectiveness of a resolution on a material change to the company's business objects depends on the buyout of the shares from those shareholders who do not agree to such a change, unless the Articles of Association contain a provision allowing for a material change to the company's business objects without a buyout provided the resolution is adopted by a majority of two-thirds of all votes in the presence of persons representing at least half of the share capital. The Issuer's Articles of Association do not contain provisions according to which a material change to the scope of the Issuer's business activity made in compliance with the conditions specified in Article 417 § 4 of the CCC would not require a buyout of shares from shareholders who do not agree to the change.

7.2. Corporate rights vested in the Issuer's shareholders

Right to request that an Extraordinary General Meeting be convened and that specific matters and draft resolutions be put on the agenda (Articles 400-401 CCC)

One or more shareholders representing at least one twentieth of the share capital may request that an extraordinary general meeting be convened and that specific items be put on the agenda of that meeting; the Articles of Association may authorise shareholders representing less than one twentieth of the share capital to request that an extraordinary general meeting be convened. The request that an extraordinary general meeting be convened shall be submitted to the management board in writing or in electronic form.

If the Extraordinary General Meeting is not convened within two weeks from the day the request was submitted to the Management Board, the court of registration may authorise the shareholders who have made said request to convene the Extraordinary General Meeting. The court shall appoint the Chair of that Extraordinary General Meeting. The meeting shall pass a resolution determining whether the costs of convening and holding the meeting are to be borne by the company. The shareholders at whose request a meeting is convened may apply to the registry court for exemption from the obligation to cover the costs imposed by the resolution of the meeting. A shareholder or shareholders representing at least one-twentieth of the share capital may require that specific items be put on the agenda of the next general meeting. The request shall be submitted to the Management Board no later than twenty-one days before the set date of the meeting. The request must include a justification or a draft resolution regarding the proposed agenda item. The request may be submitted in electronic form. The Management Board is obliged to announce the changes to the agenda introduced at the request of the shareholders immediately, but no later than eighteen days before the set date of the General Meeting.

A shareholder or shareholders of a publicly-traded company representing at least one-twentieth of the share capital may, prior to the date of the general meeting, submit to the company, in writing or using electronic means of communication, draft resolutions on the issues included in the agenda of the general meeting or on the issues to be included in the agenda. The company shall immediately publish the draft resolutions on its website. Each shareholder may, during the general meeting, propose draft resolutions concerning items on the agenda.

Right to participate in the General Shareholders Meeting (Articles 406¹-406³ CCC)

Only persons being shareholders of the company sixteen days before the date of the general meeting (date of a general meeting participation registration) have the right to participate in the general meeting of a public company. The date of a general meeting participation registration shall be the same for all beneficial holders of bearer and registered shares. The holders of registered shares and temporary certificates, as well as pledgees and users with voting rights, have the right to participate in the general meeting of a public company if they are entered in the share register on the date of a general meeting participation registration.

Bearer shares in certificated form confer the right to participate in a general meeting of a public company if the share documents are deposited with the company no later than on the date of a general meeting participation registration and are not withdrawn before the end of that date. Instead of shares, a certificate issued as proof of deposit of shares may be submitted to a notary, a bank or an investment firm having its registered office or branch on the territory of the European Union or of a country that is a party to the agreement on the European Economic Area, indicated in the notice convening the general meeting. The certificate shall indicate the numbers

of the share certificates and shall state that the share certificates will not be issued before the date of a general meeting participation registration.

At the request of a holder of dematerialised bearer shares in a public company made not earlier than after the announcement of the general meeting and no later than on the first working day after the date of a general meeting participation registration, the operator of the securities account shall issue a registered certificate of entitlement to participate in the general meeting. The list of the persons entitled under bearer shares to participate in the General Meeting of a public company shall be established by the company on the basis of the shares submitted to the company in accordance with applicable laws and the list prepared by the entity keeping the depository for securities in accordance with the regulations on trading in financial instruments. The entity keeping the securities depository shall prepare the list on the basis of lists submitted no later than twelve days before the date of the general meeting by entities authorised in accordance with the regulations on trading in financial instruments. The basis for the preparation of the lists submitted to the entity keeping the depository for securities shall be certificates of the right to participate in a general meeting of a public company. The entity keeping the depository for securities shall make the list available to a public company by means of electronic communication no later than one week before the date of the General Meeting. Where, for technical reasons, the list cannot be made available in this manner, the depository entity shall issue that list in the form of a written document no later than six days before the date of the general meeting; the issue shall take place at the registered office of the governing body of the entity.

Right to vote at the General Meeting (Article 411 CCC)

A share shall carry one vote in the General Meeting. A shareholder may vote differently on each of the shares held. A shareholder may exercise his or her voting right personally or by proxy (Article 412 § 1 CCC). Each share, unless it is privileged, shall grant the right to one vote at the General Meeting. In a public company, a member of the Member of the Management Board and an employee of the company may be a proxy at a general meeting (Article 412² CCC). Pursuant to Article 412² § 3 of the CCC, if a member of the Member of the Management Board or another person listed in that article is the shareholder's proxy, the proxy may authorise representation at only one general meeting. Pursuant to Article 412² § 4, the proxy referred to in § 3 shall vote in accordance with the instructions given by the shareholder.

Right of appeal against resolutions of the General Meeting (Articles 422-427 CCC)

A resolution of the General Meeting which is in conflict with the Articles of Association or good practice and which harms the interests of the Company or is intended to harm a shareholder, may be challenged by means of an action for revocation brought against the Company.

Right to bring an action for annulment of a General Meeting resolution

The right to bring an action for revocation of a resolution of a general meeting that is contrary to the Articles of Association or good practice and prejudicial to the interest of the company or intended to harm a shareholder may be challenged by way of an action for revocation of a resolution brought against the company by the Management Board, the Supervisory Board and individual members of these bodies or by a shareholder who:

- 1) voted against the resolution and after its adoption requested that his/her objection be recorded in the minutes (the voting requirement does not apply to silent shares),
- 2) was unjustifiably prevented from participating in the General Meeting,
- 3) was not present at the General Meeting when the General Meeting was convened in a defective manner or a resolution was adopted on a matter not included in the agenda.

In the case of a public company, the time limit for bringing action shall be one month from obtaining information on the resolution, but no later than three months from the date of the resolution.

The entities referred to above shall have the right to bring an action against the company for invalidity of a resolution of the general meeting which is contrary to the law. An action for invalidity of a resolution adopted by a general meeting of a public company shall be brought within thirty days from the date of its announcement, but no later than within one year from the date of the resolution (Art. 424 § 2 CCC).

The right to obtain information about the Company to the extent and in the manner prescribed by law (Article 428 CCC)

During the General Meeting, the Management Board is obliged to provide a shareholder at his/her request with information concerning the Company, if this is justified for the assessment of the matter on the agenda. The

Management Board may provide information in writing outside the General Meeting if there are important reasons for doing so, but no later than two weeks from the date of the request during the General Meeting. The Management Board shall refuse to provide information if this might damage the company or its related company or a subsidiary company or cooperative, particularly as a result of disclosure of technical, commercial or organizational secrets of the enterprise. A management board member may refuse to provide information if providing it might be the grounds for his/her criminal, civil or administrative liability. The answer shall be deemed given if relevant information is available on the company's website in a place designated for asking questions by the shareholders and giving them answers. Where a shareholder submits, outside the general meeting, a request for information concerning the company, the management board may provide the shareholder with information in writing. A shareholder who was refused requested information during the general meeting and who reported an objection to the minutes may apply to the registration court requesting that the management board be obliged to furnish the information as prescribed in Article 428 § 1 CCC (Article 429 § 1 CCC) or that the Issuer be obliged to publish such information as was provided to another shareholder outside the general meeting under Article 428 § 5 and 6 CCC (Article 429 § 2 CCC).

Right of action against members of the Issuer's authorities or other persons who have caused damage to the Issuer (Articles 486-487 CCC)

If the Issuer fails to bring an action for remedying the damage caused to it within one year from the date of disclosure of the act causing the damage, any shareholder or person who has another title to participate in the profits or distribution of assets may bring an action for remedying the damage caused to the Issuer, and the persons obliged to remedy the damage may not rely on the General Meeting's resolution granting them discharge or on the Issuer's waiver of claims for damages.

Right to demand that the Company's Supervisory Board be elected by a vote held in separate groups (Article 385 § 3 CCC)

At the request of shareholders who represent no less than one-fifth of the share capital, the supervisory board shall be elected by a vote held in separate groups, even if the Company's Articles of Association provide for a different manner of appointing the Supervisory Board.

Right to demand, that a commercial company being a shareholder of the Issuing Party provide information in a written form, as to whether it is in a relationship of dominance or dependency, as understood by Article 4 § 1 (4) CCC, with a specified commercial company or cooperative being a shareholder of the Issuer (Article 6 § 4 and § 5 CCC)

A shareholder, partner, member of the Management Board or of the Supervisory Board of the Issuer has the right to request a commercial company to provide information, in writing, as to whether it remains in a relation of dominance or dependency, as understood by the aforementioned regulations of the Commercial Companies Code, with a specified commercial company or cooperative being also a shareholder of the Issuer. A shareholder, partner, member of the Issuer's Management Board or Supervisory Board may also demand that he/she be informed about the Issuer's number of shares or the number of votes it holds during the General Meeting, including also in the capacity of a pledgee or user, or under agreements with other persons. The request for information and response shall be submitted in writing.

Rights related to the Issuer's documentation

- The right to inspect the share register and to request a copy of an entry in the share register (Article 341 CCC).
- The right to receive copies of the Management Board's report on the Issuer's activities and the Board's financial statement together with a copy of the Supervisory Board's report and the auditor's opinion (Article 395 CCC).
- The right to access information and documentation relating to the General Meeting arising out of the Company's obligation to post it on its website (Article 402² CCC).
- The right to inspect the list of shareholders at the Company's premises, the right to request a copy of the list of shareholders authorised to participate in the General Meeting, the right to request a copy of motions concerning matters included in the agenda of the General Meeting, the right of a shareholder to request that the list of shareholders be sent to him/her free of charge by email (Article 407 CCC).
- The right to inspect the book of minutes of the General Meeting and the right to receive copies of resolutions certified by the Management Board, the right of access to the results of votes resulting from the Company's obligation to post them on its website (Article 421 CCC).

- The right to review documents related to merger, division or transformation of the Issuer (Articles 505, 540, 561 CCC).
- The right of a shareholder or shareholders of a public company, owning at least 5% of the total number of votes, to demand that the General Meeting adopt a resolution ordering that a particular issue be examined by an auditor, at the expense of the Issuer, related to the formation of the company or to the management of its affairs (special affairs auditor); these shareholders may demand that an Extraordinary General Meeting be called for this purpose or that this resolution be put on the agenda of the next General Meeting, and that a request be made to the Register Court for appointment of the auditor (Articles 84 and 85 of the Act on Public Offer).

8. Designating of the persons managing and supervising the Issuer, of the Authorised Advisor, and of the entities carrying out audits of the Issuer's financial statements (with an indication of the auditors carrying out the audit)

The persons managing and supervising the Issuer

As at the date of this Information Document, the Management Board of the Issuer consists of:

- Piotr Garstecki - President of the Management Board
- Marcin Izydorzak - Member of the Management Board
- Szymon Ruta - Member of the Management Board

As at the date of this Information Document, the Supervisory Board of the Issuer consists of:

- Robert Przytuła - Chair of the Supervisory Board,
- Andrzej Chądzyński - Member of the Supervisory Board,
- Robert Hołyst - Member of the Supervisory Board
- Piotr Michalski - Member of the Supervisory Board,
- Patryk Mikucki - Member of the Supervisory Board,

The persons managing the Authorised Advisor

As at the date of this Information Document, the Management Board of the Authorised Advisor consists of:

- Michał Kowalczewski - President of the Management Board
- Bogusław Galewski - Vice President of the Management Board
- Robert Drążykowski - Member of the Management Board

As at the date of this Information Document, the Authorised Advisor possesses no supervising persons.

Entities auditing the Issuer's financial statements

The financial statements for 2018 were audited by KPMG Audyt Sp. z o.o. sp. k. with its principal place of business in Warsaw, an entity entered in the list of entities authorised to audit financial statements maintained by the National Council of Statutory Auditors under number 3546. The key auditor conducting the audit was Wojciech Drzymała, entered in the list of persons authorised to audit financial statements under number 90095. The 2017 financial statements were audited by KPMG Audyt Sp. z o.o. sp. k., with its principal place of business in Warsaw, an entity entered in the list of entities authorised to audit financial statements kept by the National Council of Statutory Auditors under number 3546. The key auditor conducting the audit was Wojciech Drzymała, entered in the list of persons authorised to audit financial statements under number 90095.

9. Basic information on the Issuer's capital links which may have a significant impact on its activities, with an indication of significant entities of its capital group, including in relation to each of them at least the name, legal form, registered office, object of activity, and the Issuer's share in the share capital and the total number of votes

As of the date of the Information Document, the Issuer holds shares in the following companies:

- 1) Curiosity Diagnostics Sp. z o.o. with its principal place of business in Warsaw at ul. Duchnicka 3, Building 16, Entrance A, KRS 417594. The Company's share capital is PLN 8,094,000.00 and is divided into 161,880

shares with a nominal value of PLN 50.00 each. The Issuer holds 161,880 shares with the total nominal value of PLN 8,094,000, accounting for 100% of the share capital and the total number of votes.

2) Bacteromic Sp. z o.o. with its principal place of business in Warsaw at ul. Duchnicka 3, Building 16, Entrance A, KRS 666549. The Company's share capital is PLN 1,505,000.00 and is divided into 30,100 shares with a nominal value of PLN 50.00 each.

The Issuer holds 30,100 shares with the total nominal value of PLN 1,505,000, accounting for 100% of the share capital and the total number of votes.

Curiosity Diagnostics Sp. z o.o. and Bacteromic Sp. z o.o. were established for the purpose of separate projects, i.e. research and development work. Curiosity Diagnostics Sp. z o.o. is dedicated to the development of the PCR|ONE system, while Bacteromic Sp. z o.o. is dedicated to the development of the BACTEROMIC system.

10. Basic information on personal, property and organisational relations

10.1. Personal, property and organisational relations between the Issuer and persons being members of the Issuer's management and supervisory bodies

Piotr Garstecki - President of the Management Board is, at the same time, a shareholder of the Issuer holding approximately 14.6% of the votes at the General Meeting as of the date of the Information Document.

Marcin Izydorczak - Member of the Management Board is, at the same time, a shareholder of the Issuer holding approximately 14.3% of the votes at the General Meeting as of the date of the Information Document.

Szymon Ruta - Member of the Management Board is, at the same time, a shareholder of the Issuer holding approximately 2.5% of the votes at the General Meeting as of the date of the Information Document.

Robert Hołyst, Member of the Supervisory Board, is also a shareholder of the Issuer holding approximately 1.6% of the votes at the General Meeting as of the date of the Information Document.

10.2. Personal, property and organisational links between the Issuer or members of its management and supervisory bodies and the Issuer's major shareholders

Robert Przytuła, Chairman of the Supervisory Board, is also manager of TOTAL FIZ fund, which holds, both directly and indirectly, as of the date of this Information Document, approximately 26.1% of the votes at the General Meeting.

10.3. Personal, property and organisational links between the Issuer, persons being members of its management and supervisory bodies and significant shareholders of the Issuer and the Authorised Advisor

There are no personal, property or organisational relations between the Issuer, persons being members of its management and supervisory bodies and significant shareholders of the Issuer, and the Authorised Advisor or persons being members of its management and supervisory bodies.

11. Key risk factors relating to the Issuer and the financial instruments being introduced

11.1. Risk factors related to the environment in which the Issuer operates

11.1.1. Risks related to the macroeconomic situation

The implementation of the Issuer's strategic goals is influenced by, among other things, macroeconomic factors. In the nearest future they include, in particular, factors influencing the so-called investment climate (inflation levels, interest rates levels, stock exchange indices, the general condition of the Polish and global economies), which is favourable for investors taking decisions on capital participation in *spin-off* companies. The deterioration of the general economic situation in Poland and worldwide may result in a more difficult access to investment capital and, consequently, adversely affect the implementation of the Issuer's research and development projects.

11.1.2. Risks related to a possible disclosure of business secrets

The implementation of the Issuer's plans may be dependent on keeping secret confidential information relating to its research and development activities. There is a risk that such information will be disclosed and used by persons or companies cooperating with the Issuer. Using such information, in particular by entities conducting activities that are competitive in relation to the Issuer, may adversely impact the effect of commercialisation of the Issuer's research and development projects. In order to limit that risk, the Issuer signs confidentiality agreements with both employees and companies cooperating with the Issuer in areas concerning research and development works.

11.1.3. Risks related to legal regulations and the possibility of their change

Legal regulations affecting the Issuer's legal environment undergo frequent changes in Poland. Any such changes, in turn, carry a risk of adversely affecting the Issuer's operations and development plans. Additionally, it should be noted that the regulations are characterised by a high degree of diversity in terms of their interpretation. This means that even if the Issuer exercises due diligence, the decisions it makes may ultimately prove unfavourable to it.

11.1.4. Risks related to disputes concerning intellectual and industrial property rights

The Issuer operates in an area where regulations concerning intellectual property rights and their protection are of significant importance. As of the date of this Information Document, there are no proceedings pending for infringement of intellectual property rights. The Issuer intends to conduct its business in such a way as not to infringe the rights of third parties in this respect. However, it cannot be excluded that claims will be filed against the Issuer by third parties regarding infringement of industrial and intellectual property rights by the Issuer. Such claims, even if unfounded, may adversely affect the timetable for the implementation of the Issuer's strategy, and defending against such claims may require incurring significant costs, which could adversely affect the Issuer's financial performance.

11.1.5. Risk of changes in tax legislation and ambiguous interpretation thereof

The Issuer is subject, in connection with its operations, to a variety of taxes. There is a risk that tax changes resulting from changing governmental tax policies may adversely affect the Issuer's business and financial condition. The Issuer monitors tax changes and takes them into account in the decision-making process.

11.2. Risk factors related to the Issuer's activities

11.2.1. Foreign exchange risk

A significant portion of the basic raw materials and components used by the Issuer in its research and development activities is purchased from foreign suppliers. The settlement currencies are the euro and the US dollar. Unfavourable exchange rate changes (weakening of PLN against EUR and USD) may therefore result in a significant increase in operating costs, which, as a result, may adversely affect the Issuer's operations and exceed the R&D budget.

11.2.2. Competition risks

The Issuer's strategic objective is to complete research and development work on PCR|ONE and BACTEROMIC diagnostic systems and to market them as the most innovative devices in a specific diagnostic field. There is a risk that parallel to the work carried out by the Issuer and its special purpose vehicles, other scientific and technical teams carry out research and development work in the same field. Thus, there is a risk that before the systems developed by the Issuer are commercialised, other devices with better or comparable technical properties to PCR|ONE and BACTEROMIC will appear on the market. In order to reduce this risk, the Issuer conducts activities in the field of patent protection of its solutions, monitors the market of diagnostic devices on an ongoing basis, and monitors specialist and scientific publications and patent databases.

11.2.3. Supplier risks

As part of its operations, the Issuer relies on supply of selected biological materials and reagents from a limited number of suppliers, which, if supplies from those suppliers are discontinued, may involve a risk that the Issuer may reduce, halt or slow down its research and development activities. An increase in the prices of supplies of materials and reagents may result in an increase in the cost of ongoing research and development work. In order

to mitigate this risk, the Issuer tries not to limit itself to one supplier or, if necessary, seeks to identify an alternative supplier.

11.2.4. Risks related to staff

The Issuer conducts its business based on the knowledge and technological experience of its highly qualified management staff and specialists. The possible loss of key employees may cause significant difficulties related to the continuation and completion of research and development work on ongoing projects, which may have an adverse effect on the Issuer's business and financial performance.

11.2.5. Risks related to loss of key resources (prototypes, research documentation)

A loss of resources arising from the research work (prototypes, research documentation) may result in an extension of the deadline for completion of projects and/or increase expenses related to their completion. Additionally, such loss of resources may result in a disclosure of business secrets.

11.2.6. Risks related to the work schedule

Completion of research and development work involves a need to meet a work schedule that spans several years. The ability to meet this schedule is affected by a variety of factors, both internal and external. Potential occurrence of unforeseen delays in the implementation of the adopted schedule may adversely affect the Issuer's financial position.

11.2.7. Risks related to registration tests

One of the stages in the development of diagnostic systems is registration tests conducted in external laboratories. There is a risk that the planned test results may not be obtained, which may result in the need to modify the components of the PCR|ONE or BACTEROMIC system, thus negatively affecting the timescale of the commercialisation of the devices or increasing the total cost of research and development.

11.2.8. Risks related to the registration of equipment

Within the currently planned budget, the PCR|ONE and BACTEROMIC systems will be registered in Poland with the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. The registration process may not take place on the planned date or the registration will not be possible, which may adversely affect the timescale of the commercialisation of the devices or increase the total cost of research and development.

11.2.9. Risks related to business financing and the need to raise additional funds

Since 2016, i.e. since the completion and settlement of the contract for performance by the Issuer of a service commissioned by its business partner, the only sources of funding for the Issuer include contributions from its shareholders and from EU programmes. The lack of any planned sales revenues, and thus no expected operating profits means that the Issuer will continue to rely on the funding obtained as part of the Issuer's capital increase and EU subsidies to continue and complete its work on the diagnostic systems. In the event that the funding obtained from these sources are not sufficient to complete the research and development work, the Issuer will have to take steps to reduce the planned budgets, and thus the functionality of the systems, extend the time of implementation of selected stages of the development work or change the strategy and nature of the business.

11.2.10. Risk of reimbursement of EU subsidies

The grants obtained by the Group's Companies are subject to a number of conditions, the breach of which may entail the necessity to return the public funds granted to date. Both Bacteromic and Curiosity Diagnostics implement grant agreements with due diligence and in accordance with the requirements contained therein. However, there is a risk that in the event of non-compliance with the provisions contained in the above-mentioned agreements or failure to achieve all the project indicators, Bacteromic and/or Curiosity Diagnostics will be obliged to return the grant amount with due interest or a part of this amount, which may have a negative impact on the Group's operations and financial results.

11.2.11. Risks related to carrying out innovative activities

The Issuer's activities are related to very modern and innovative fields of science, which, despite the experience of the Issuer's Management Board and employees, involves the threat of risk areas that have not been included in the Issuer's assumptions and plans to date

11.3. Risk factors associated with the Issuer's financial instruments introduced in the alternative trading system and the capital market on which they will be listed

11.3.1. Risks related to a refusal or delay in the introduction of shares to trading in the alternative trading system

Shares are introduced to trading in the alternative system upon the issuer's request. According to ASO the Alternative Trading System Rules, the Stock Exchange, as the ATS Organizer, may object to the introduction of financial instruments referred to in the application to trading.

A refusal to do so may result in suspension or complete discontinuation of the process of introducing the Issuer's shares to the Alternative Trading System.

Pursuant to § 5 (2) of the ATS Rules, the Alternative Trading System Organiser shall adopt a resolution to refuse the introduction to trading in the alternative trading system of financial instruments referred to in the application if:

1. the conditions for introduction set out in the ATS Rules have not been met;
2. it decides that the introduction of particular financial instruments to trading would jeopardise the trading safety or the interests of the trading participants, and when assessing the application in this respect the Alternative Scheme Organiser shall, taking into account the type of financial instruments covered by the request, take into account in particular:
 - a. the dispersion of the financial instruments covered by the application from the point of view of liquidity of trading in those instruments in the alternative system,
 - b. the conditions and manner in which the offer of the requested financial instruments is to be made,
 - c. the issuer's business and its prospects for growth, including the sources of its funding; or
3. decides that the information document substantially differs from the formal requirements specified in Appendix 1 to the ATS Rules.

Where the Alternative System Organiser adopts a resolution refusing the introduction of the financial instruments referred to in the application to trading in the alternative system, it must give specific reasons for its decision and promptly provide the issuer with a copy of the relevant resolution together with the related specific reasons.

Within 10 business days of the date of delivery of a copy of the resolution refusing the introduction, the issuer may submit in writing an application for reconsidering the case. The Alternative System Organiser shall consider that application as soon as possible but no later than within 30 business days of its filing, after obtaining an opinion of the Exchange Supervisory Board.

If it is necessary to obtain additional information, statements or documents, the time limit for consideration of such application shall run from the date of delivery of the required information. If the Alternative System Organiser decides that the application for reconsideration is fully justified, it may repeal or amend the appealed resolution without consulting the Exchange Supervisory Board.

11.3.2. Risk related to a decision to suspend or exclude financial instruments from trading in the alternative system

Pursuant to § 11 of the ATS Rules, the Alternative Trading System Organiser may suspend trading in financial instruments:

- at the issuer's request;
- if it finds that the safety of trading or the interest of trading participants requires it;
- if the issuer is in breach of the rules applicable in the alternative system.

Pursuant to § 11 (1a) of the ATS Rules, when suspending trading in financial instruments, the Alternative System Organiser may set a time limit until which the trading suspension shall remain in force. That period may be extended accordingly upon request of the issuer or if, in the opinion of the Alternative System Organiser,

there is reasonable concern that on the day of expiry of that period the circumstances referred to in subparagraph 1 (2) or (3) will occur.

Pursuant to § 11 (2) of the ATS Rules, in cases set out in applicable laws, the Alternative System Organiser shall suspend trading in financial instruments for a period resulting from those laws or specified in a decision of a relevant authority.

According to § 11 (3) of the ATS Rules, the Alternative System Organiser shall suspend trading in financial instruments immediately after becoming aware of the suspension of trading in relevant instruments on the regulated market or in the alternative trading system operated by BondSpot S.A, if such suspension is related to the suspicion of insider dealing, illegal disclosure of inside information, market manipulation or suspicion of breach of the obligation to publish inside information about the issuer or financial instrument in breach of Article 7 and Article 17 of the MAR Regulation, unless such suspension could cause a serious damage to the investors' interests or the orderly functioning of the market.

Pursuant to § 12 (1) of the ATS Rules, the Alternative System Organiser may delist financial instruments from trading:

- 1) on request of the issuer of the shares if the exclusion of the shares concerned from trading is due to their admission to trading on a regulated market;
- (1a) upon request of the issuer of other financial instruments, provided that such a decision may be made subject to additional conditions to be met by the issuer,
- 2) where it finds that the safety of trading or the interests of trading participants so require;
- 3) if the issuer persistently breaches the rules applicable in the alternative system;
- 4) due to the opening of liquidation of the issuer;
- 5) as a result of a decision to merge the issuer with another entity, to split the issuer, or to transform the issuer, whereby the exclusion of financial instruments from trading may not take place earlier than on the date of the merger, the date of the split (spin-off), or the date of the transformation, respectively.

Pursuant to § 12 (2) of the ATS Rules, the Alternative System Organiser delists or, as appropriate, withdraws financial instruments from trading in the alternative system:

- 1) in cases provided for by law, in particular:
 - a) if the Financial Supervision Authority grants permission for the shares to be delisted from the alternative trading system,
 - b) in the case of shares, 6 months after a decision on the declaration of bankruptcy of the issuer of the shares or a court decision dismissing the application for a declaration of bankruptcy of the issuer of the shares on the grounds that its assets are insufficient or are sufficient only to cover the costs of the proceedings;
- 2) if the transferability of those instruments has become restricted;
- 3) in the event of a removal of dematerialisation of those instruments;
- 4) in the case of debt financial instruments - after a decision on declaration of bankruptcy of the issuer of debt financial instruments or a court decision dismissing the application for declaration of bankruptcy of the issuer of debt financial instruments on the grounds that its assets are insufficient or sufficient only to cover the costs of the proceedings or a court decision on discontinuance of bankruptcy proceedings of the issuer of debt financial instruments on the grounds that its assets are insufficient or sufficient only to cover the costs of the proceedings.

Pursuant to § 12 (3) of the ATS Rules, before taking a decision to delist a financial instrument from trading and until such delisting, the Alternative System Organiser may suspend trading in that financial instrument.

According to § 12 (4) of the ATS Rules, the Alternative System Organiser shall delist financial instruments from trading immediately after becoming aware that such instruments were delisted from the regulated market or alternative trading system operated by BondSpot S.A, if such delisting is related to the suspected use of inside information, illegal disclosure of inside information, market manipulation or suspected breach of the obligation to publish inside information about the issuer or financial instrument in breach of Articles 7 and 17 of the MAR Regulation, unless such delisting would result in a serious damage to the investors' interests or the orderly functioning of the market.

Pursuant to § 12a of the ATS Rules, taking a decision to delist financial instruments from trading, the Alternative System Organiser must give specific reasons for its decision and promptly provide a copy thereof together with the related specific reasons to the issuer and its Authorised Advisor by fax or electronically to that entity's last email address indicated to the Alternative System Organiser.

Within 10 business days of the date of delivery of the decision to delist the issuer, the issuer may submit in writing an application for reconsidering the case. The application shall be deemed filed on the day the original application is received at the office of the Alternative System Organiser.

The Alternative System Organiser must consider the application for reconsideration immediately but no later than within 30 business days from its filing date after obtaining an opinion of the Exchange Supervisory Board. If it is necessary to obtain additional information, statements or documents, the time limit for consideration of such application shall run from the day of delivery of the required information. If the Alternative System Organiser decides that the application for reconsideration should be fully accepted, it may repeal or amend the appealed decision without consulting the Exchange Supervisory Board.

The decision on exclusion from trading shall be enforced 5 working days after the expiry of the deadline for submitting an application for reconsideration of the case or, if an application is submitted, 5 working days after the date it was considered and the decision on exclusion was upheld. Until these deadlines expire, trading in the financial instruments concerned shall be suspended.

A subsequent application for introduction of the same financial instruments to trading in the alternative system may be filed not earlier than upon the lapse of 12 months after the date of delivery of the resolution on delisting the financial instruments from trading or, where an application for reconsidering the case is filed, not earlier than upon the lapse of 12 months after the date of delivery to the issuer of the resolution that the delisting decision was upheld. This provision applies accordingly to the other financial instruments of the particular issuer. This limitation shall not apply when the exclusion of particular financial instruments from trading was requested by their issuer and in cases referred to in § 12 (2) Items 1) - 4).

The Exchange shall immediately notify the Financial Supervision Authority of the suspension of trading, resumption of trading or exclusion of financial instruments from trading. Information on the suspension of trading, resumption of trading or exclusion of financial instruments from trading shall be promptly made public in the manner set out in Article 3 (1) of Commission Implementing Regulation (EU) 2017/1005.

Pursuant to § 17b of the ATS Rules, if in the opinion of the Alternative System Organiser it is necessary for the issuer to continue its co-operation in the performance of its disclosure obligations with an entity authorised to perform the tasks of Authorised Advisor, the Alternative System Organiser may obligate the issuer to make an agreement to the extent set out in § 18 (2) items (3) and (4). The agreement shall be made within 20 business days from the date of the relevant decision by the Alternative System Organiser and remain in force for at least one year after it is entered into.

If the agreement with the Authorised Adviser is terminated or expires before the end of the period indicated in the Alternative System Organiser's decision adopted pursuant to sub-paragraph 1, the issuer must make a new agreement with the Authorised Adviser within 20 business days after the termination or expiry of the previous agreement. The new agreement shall remain in force until the end of the period indicated in the decision of the Alternative System Organiser, provided that its term shall be prolonged by the period during which the issuer did not have a legally binding agreement with the Authorised Adviser which the issuer was obliged to execute under the decision of the Alternative System Organiser referred to in sub-paragraph 1.

If the issuer fails to make an agreement with the Authorised Adviser or if such agreement does not come into force within the time limit referred to in sub-paragraph 1 or within 20 business days after the termination or expiry of the previous agreement as referred to in sub-paragraph 2, the Alternative System Organiser may suspend trading in the financial instruments of that issuer. If before the lapse of 3 months from the start of the suspension an appropriate agreement with the Authorised Adviser has not been made and entered into force, the Alternative System Organiser may delist the financial instruments of that issuer from the alternative system.

Pursuant to § 17c of the ATS Rules, if an issuer fails to comply with the rules or regulations applicable in the Alternative Trading System or fails to perform or performs inappropriately the obligations existing in the Alternative Trading System, in particular those set out in §15a and 15b or §17-17b of the ATS Rules, the Alternative Trading System Organiser may, depending on the degree and scope of the occurring violation or irregularity:

- admonish the issuer;
- impose a fine on the issuer of up to PLN 50,000.

The Alternative Trading System Organiser, when taking a decision to impose a caution or a fine, may set a time limit for the issuer to refrain from past violations or to take actions aimed at preventing future violations, in particular it may oblige the issuer to publish specific documents or information according to the procedure and on conditions applicable in the Alternative Trading System.

If an issuer fails to perform the penalty imposed on it or fails to comply with the rules or regulations applicable in the alternative trading system, or fails to perform or inappropriately performs the obligations set out in this Chapter, or fails to perform the obligations imposed on it pursuant to sub-paragraph 2, the Alternative System Organiser may impose a fine on the issuer, but such fine together with the fine imposed under sub-paragraph 1 (2) shall not exceed PLN 50,000.

According to § 17d of the Alternative Trading System Rules, the ATS organiser may publish on its website information about a violation by an issuer of the rules or regulations applicable in the Alternative Trading System, about the issuer's failure to perform its obligations or perform them appropriately, or about a penalty imposed on the issuer. In such information, the Alternative Trading System Organiser may provide the name of the entity which acts as an authorised advisor to the issuer.

Pursuant to Article 78 (2) of the Act on Trading in Financial Instruments, if required for the safety of trading in the Alternative Trading System or if investors' interests are jeopardised, the Alternative Trading System Organizer shall, at the request of the Commission, suspend the introduction of the financial instruments to trading in this alternative system or suspend the commencement of trading in particular financial instruments for a period not longer than 10 days.

Pursuant to Article 78 (3) of the Act on Trading in Financial Instruments, if trading in specific financial instruments is carried out in circumstances which indicate a possible threat to the proper operation of the Alternative Trading System or to the security of trading in this alternative system, or a possible infringement of investors' interests, the Organizer of the Alternative Trading System shall, at the request of the Commission, suspend trading in such financial instruments.

Pursuant to Article 78 (4) of the Act on Trading in Financial Instruments, at the request of the Commission, the organiser of the Alternative Trading System shall delist financial instruments indicated by the Commission if trading in them materially threatens the proper functioning of the Alternative Trading System or the security of trading in this alternative system, or results in a breach of investors' interests.

Information about the suspension or delisting of financial instruments from trading shall be published immediately on the website of the Alternative Trading System organiser.

Pursuant to the Article 78 (4a) of the Act on Trading, the Stock Exchange as the Organizer of the Alternative Trading System may take a decision to suspend or delist securities in the event such instruments no longer meet the conditions applicable on this market on condition that this will not cause a significant infringement of investors' interests or a threat to the proper functioning of the market. The Exchange as the Organizer of the Alternative Trading System shall inform the Commission of its decision to suspend or delist the financial instruments from trading and make that information public.

Suspension of or delisting from trading in the alternative system may have a negative impact on the liquidity of the shares in secondary trading and on their market value, and, in particular, may hinder their disposal by shareholders.

This risk applies to the shares of all companies listed on NewConnect.

11.3.3. Risk related to the possibility that the Polish Financial Supervision Authority may impose administrative penalties on the issuer for non-performance or improper performance of obligations under the law

The companies listed on NewConnect have the status of a public company within the meaning of the Act on Trading in Financial Instruments; consequently, the Financial Supervision Authority may impose administrative penalties on an issuer for failure to perform or inadequate performance of its obligations under the law, in particular the obligations arising from the Act on Public Offering and the Act on Trading in Financial Instruments.

Where the Issuer fails to fulfil or inadequately fulfils its duties as referred to in Article 96 (1) of the Act on Public Offer, the Commission may issue a decision on exclusion of its securities from trading on the regulated market, and if the Issuer's securities are introduced to trading in an alternative trading system, a decision on exclusion of these securities from trading in this system, or impose a monetary penalty of up to PLN 1,000,000, taking into account, in particular, the financial situation of the entity on which the penalty is imposed, or apply both sanctions together.

Pursuant to Article 30 of the MAR Regulation, the Authority of the Financial Supervisory Commission has been granted the power to apply appropriate administrative sanctions and other administrative measures, up to the maximum amount and to the extent as, at least, specified in Article 30 (2) of the MAR Regulation.

Pursuant to Article 30 (2) of the MAR Regulation, in the case of violations set out in the MAR Regulation related, among other things, to insider trading, market manipulation and abuse, public disclosure of inside information, transactions by persons discharging managerial responsibilities, insider lists, in the case of legal persons, Member States shall ensure, in conformity with national law, that the competent authorities shall have the power, among other things, to impose the following administrative pecuniary sanctions (maximum administrative pecuniary sanctions of at least):

- a) in the case of infringements of Articles 14 and 15 of the MAR Regulation, EUR 15,000,000 or 15% of the total annual turnover of the legal person based on the latest available report approved by the management body and, in a Member State where the currency is not the euro, the equivalent in national currency of that amount as of 2 July 2014,
- b) in the case of infringements of Articles 16 and 17 of the MAR Regulation, EUR 2,500,000 or 2% of the total annual turnover on the basis of the latest available report approved by the management body or, in a Member State where the currency is not the euro, the equivalent in national currency of that amount as of 2 July 2014, and
- c) in the case of infringements of Articles 18, 19 and 20 of the MAR Regulation, EUR 1,000,000 or, in a Member State where the currency is not the euro, the equivalent in national currency of that amount as of 2 July 2014.

Pursuant to Article 96 (1i) of the Act on Public Offer, where the Issuer fails to fulfil or unduly fulfils its duties as referred to in Article 17 (1) and (4)-(8) of the MAR Regulation, the Commission may issue a decision on exclusion of its securities from trading on the regulated market and, if the Issuer's securities are introduced to trading in an alternative trading system, a decision on exclusion of these securities from trading in this system, or impose a monetary penalty of up to PLN 10,364,000 or an amount equivalent to 2% of the total annual income disclosed in the last audited financial statements for the financial year if it exceeds 10,364,000 PLN, or apply both sanctions jointly.

Furthermore, pursuant to paragraph 1k) - where it is possible to determine the amount of the benefit gained or the loss avoided by the issuer as a result of a breach of the obligations referred to in paragraph 1i), instead of the penalty referred to in those provisions, the Commission may impose a financial penalty of up to three times the amount of the benefit gained or the loss avoided.

Where it is established that there has been a breach of the obligations referred to in paragraph 1i), the Commission may require the party in breach to put an end to the breach, and may require the party in breach to

take action within a specified period to prevent future infringements. This measure may be applied notwithstanding the application of the other sanctions referred to in paragraph 1i). This risk applies to the shares of all companies listed on NewConnect.

11.3.4. Risk of investing in the NewConnect market

Acquiring the Company's shares, an investor should be aware that the risk of direct investment in shares on the capital market is significantly higher than the risk of investment in treasury securities or participation units in investment funds. The NewConnect market is characterised by particularly high share price volatility combined with relatively low liquidity of trading. Investing in shares on the NewConnect market must be considered in the medium and long term. The Alternative Trading System is subject to a risk of changes in the Company's share price, which may or may not reflect the Company's current economic and market situation.

11.3.5. Risk of low liquidity of the market and shares on the market

The prices of shares listed on NewConnect may be subject to significant fluctuations, depending on the development of supply and demand relationships. These relationships depend on many complex factors, including in particular unpredictable investment decisions made by individual investors. Many factors affecting the prices of shares listed in the Alternative Trading System are independent of the situation and actions of the issuer. At the same time, shares listed in the Alternative Trading System are characterised by lower liquidity than securities listed on the regulated market. In addition, due to the Company's shareholding structure, there is a risk that the number of shares actually traded on the market may be small in practice.

There is therefore a risk that a holder of the Company's shares will not be able to sell them at a time of his/her choosing and at a satisfactory price. In extreme cases, there is a risk of incurring losses as a result of selling the shares at a price lower than their purchase price. Similarly, there is a risk that a person interested in acquiring the Company's shares as part of a transaction concluded in the Alternative Trading System may not be able to purchase such shares at the time selected by him/her or at the expected price.

In order to maintain the liquidity of trading in its securities, the Issuer has signed a market making agreement with an entity authorised to perform such function.

12. Information on the Issuer

12. 1 Brief history of the Issuer

The most significant events in the history of the Issuer's operations are set out below.

2010	August - Establishment of Scope Fluidics Sp. z o.o. by Piotr Garstecki, Marcin Izydorzak and Robert Hołyst. The share capital of Scope Fluidics Sp. z o.o. is PLN 10,000.00 and is divided into 200 shares with a nominal value of PLN 50.00 each.
2011	May - Accession to the Company of the Institute of Physical Chemistry of the Polish Academy of Sciences, which acquires 10% of the shares from the existing shareholders of the Company. Execution of a contract with PZ Cormay S.A. for the development of a system for performing biochemical tests from a single drop of blood (ANALIZATOR project).
2012	February - Establishment of Curiosity Diagnostics Sp. z o.o. to implement the PCR ONE project. The Company's share capital is PLN 50,000.00 and is divided into 1,000 shares with a nominal value of PLN 50.00 each. The Issuer acquires 40% of shares in the company. March - Total Closed Investment Fund joins the Company, acquiring 24.8% of the shares from the existing shareholders of the Company.

	<p>ANALIZATOR project - Development of the first microfluidic technology modules.</p> <p>PCR ONE project - Obtaining of EU funding of PLN 2.1 million.</p>
2013	<p>ANALIZATOR project - Development of the first prototype analyser.</p> <p>PCR ONE project - Completion of the first two stages of work on the PCR ONE system, i.e. development of the system specification and device concept.</p>
2014	<p>June - Increase in the capital of Curiosity Diagnostics Sp. z o.o. by PLN 50,000.00 through the creation of 1,000 new shares fully subscribed by all existing Company shareholders. The share capital of Curiosity Diagnostics after the increase is PLN 100,000.00 and is divided into 2,000 shares with a nominal value of PLN 50.00 each. The Issuer's share in the company remains at 40%.</p> <p>ANALIZATOR project - Optimisation of technology and production of a series of 3 prototype systems.</p> <p>PCR ONE project - Completion of next steps in development of the PCR ONE system, i.e. development of the disposable chip concept and construction of the first PCR ONE device prototype. Launch of the patent procedure for the IR invention, i.e. the module for ultra-fast PCR with integrated detection.</p>
2015	<p>November - Acquisition by the Issuer of 590 shares in Curiosity Diagnostics Sp. z o.o. from the existing Company shareholders. The Issuer's share in the company increases to 69.5%.</p> <p>ANALIZATOR project - Completion and settlement of the contract.</p> <p>PCR ONE project - Development of the next generation integrated prototype of the PCR ONE device. Application for IR invention in the international PCT procedure.</p>
	<p>April - Increase in the Issuer's share capital by PLN 11,500.00 through the creation of 230 new shares fully covered by TOTAL FIZ. The Issuer's share capital was increased to PLN 112,500.00 and divided into 2,250 shares with a nominal value of PLN 50.00 each. The total price for TOTAL FIZ to take up the Issuer's shares was PLN 2,500,000. TOTAL FIZ's share in the Company increased to 42%.</p>
2016	<p>November - Increase in the Issuer's share capital by PLN 24,500.00 through the creation of new shares taken up by the Issuer's minority shareholders in exchange for a contribution in kind in the form of shares in Curiosity Diagnostics (as a result of the exchange of shares, the Issuer becomes the owner of 94% of shares in Curiosity Diagnostics 2016. Sp. z o.o.). The Issuer's share capital was increased to PLN 137,000.00 and divided into 2,740 shares with a nominal value of PLN 50.00 each.</p> <p>PCR ONE project - Construction of 6 copies of optimised PCR ONE devices. Optimisation of the chip architecture. Start of development of PCR methodology for MRSA panel (detection of Staphylococcus aureus bacteria and genes responsible for two antibiotic resistance mechanisms). Application for the IR invention in the European Patent Office, USA and China. BACTEROMIC project - Commencement of work on the BACTEROMIC system. Acquisition of EU funding for the creation of a prototype of the BACTEROMIC system in the amount of approximately PLN 1.6 million.</p>

February - Adoption by the Extraordinary Shareholders Meeting of Scope Fluidics Sp. z o.o. of a resolution to transform Scope Fluidics Sp. z o.o. into a joint stock company. The Issuer's share capital consisted of 137,000 shares and was divided into 1,370,000 registered shares with a nominal value of PLN 0.10 each.

February - Establishment of Bacteromic Sp. z o.o. with a view to implementing the BACTEROMIC project. The Company's share capital is 5,000.00 PLN and is divided into 100 shares with a nominal value of 50.00 PLN each. The Issuer took up 100% of shares in the company.

March - Registration of the Issuer's transformation into a joint stock company by the Registry Court. May - Increase in the Issuer's share capital by PLN 90,000.00 through the issue of 900,000 new series C ordinary bearer shares with a nominal value of PLN 0.10. The Issuer's share capital was increased to PLN 227,000.00 and was divided into 2,270,000 shares with a nominal value of PLN 0.10 each. The issue price of Series C Shares was PLN 18.00 per share and the total value of the issue was PLN 16.2 million.

August - First listing of the Issuer's shares on the NewConnect market.

December - Change of address of the Issuer's registered office.

2017

PCR|ONE project - obtaining EU funding for further development of the PCR|ONE system in the amount of some PLN 5.5 million. Completion of development works on an automated chip for MRSA analysis ("direct PCR" version). Successful completion of another stage of the application procedure before the European Patent Office for the PCR|ONE system, related to the invention of ultra-fast heating-cooling and simultaneous detection. The granting by the US Patent Office of a patent for the invention entitled: *Device for simultaneous and uniform thermalcycling of samples and uses thereof*, marked by number US 9 737 892 B2. The patent relates to the technology used in the PCR|ONE diagnostic system, allowing ultra-fast PCR to be performed on multiple samples simultaneously, as well as integrating PCR and detection of reaction products in a single module. Completion of the chip optimisation stage and of development of the MRSA panel - an integrated microfluidic chip was created to perform the full automatic DNA testing procedure - isolation of nucleic acids, their amplification and detection of the reaction product. BACTEROMIC project - Completion of work on the concept and preliminary architecture of the BACTEROMIC system. Completion of the stage "Development of a prototype device, panel and pilot line for filling and closing the panels".

2018

January - Signing a letter of intent with ALAB Laboratoria regarding cooperation to improve the industrialisation process and market validation of the company's key projects, in particular the PCR|ONE system.

July - signing of an agreement with Clairfield Partners LLC to advise on the process of securing a strategic investor interested in acquiring the Curiosity Diagnostics special purpose vehicle.

December - appointment of an advisory committee to assist the Management Board in further development of the Company and to ensure the transfer of the latest medical-technological know-how.

PCR|ONE project - Completion of Clostridium difficile panel. Prevalidation of the PCR|ONE system carried out in the microbiological laboratory of ALAB Laboratoria. The system obtained high values of the most clinically relevant parameters - sensitivity and specificity. The tests confirmed that the PCR|ONE system might enter the

optimisation phase, i.e. the final stage before launching pilot production.

BACTEROMIC project - Completion of the phases "Launch of prototype and pilot panel filling and sealing (F&S) line" and "Validation of prototype and pilot F&S line. Expansion of patent portfolio.

2019 December - Increase in the Issuer's share capital by PLN 23,154.00 through the issue of 231,540 new Series F ordinary bearer shares with a nominal value of PLN 0.10. The issue price of Series F shares was PLN 60.00 per share and the total value of the issue was PLN 13.9 mln.

PCR|ONE project - Optimisation of MRSA panel design. Development of system control software. A pilot line for filling and gluing microfluidic chips was launched. Prevalidation tests in the microbiology laboratory of ALAB Laboratoria.

BACTEROMIC project - Obtaining funding under Phase 2 of the European SME Instrument programme.

12.2. Brief presentation of the Issuer's activities

Scope Fluidics is a technology start-up incubator, providing the legal, financial and infrastructural framework and critical know-how resources for projects to grow into start-up companies. Scope Fluidics focuses its attention on diagnostics and healthcare.

Project start-ups are preceded by an identification of a problem and a verification and provision of evidence for its social and business relevance. Once funding is obtained, the project is transformed into a start-up company with the aim of creating a product and bringing it to market. Once the product is on the market, the start-up company is divested to an industry investor.

A half of the funds obtained as a result of such a transaction remain in Scope Fluidics (detailed regulations are specified in the Company's Articles of Association) and are allocated to the development of further projects. The remainder, representing a multiple of the investors' contribution, is paid out as dividends to the Company's shareholders. With this solution, the Company is able to simultaneously provide investors with a return on their investment, increase its value and, in the long term, launch, commercialise and sell further projects in the field of diagnostics and healthcare.

The organisation as a whole creates an energetic, stimulating environment in which societal needs and quantified market needs collide with potential solutions, where solutions are created with the participation of and collaboration with doctors and medical staff and project managers, engineers and scientists.

Scope Fluidics is currently developing two projects in two separate special purpose vehicles.

1. The PCR|ONE system is run at Curiosity Diagnostics Sp. z o.o.
2. The BACTEROMIC system is operated by Bacteromic Sp. z o.o.

PCR|ONE system

In 2012 Scope Fluidics established Curiosity Diagnostics to develop a diagnostic system that offers the world's fastest amplification and detection of genetic material of bacterial and viral pathogens - the PCR|ONE system. The project is a response to the high societal demand for fast and effective medical diagnostics, which is a

prerequisite for modern and personalised therapy. Hospital-acquired infections affect between 5 and 10% of all hospitalised patients and are responsible for the deaths of nearly 25% of them. A fast and accurate identification of the pathogen causing the infection is essential for appropriate treatment and isolation of patients in order to stop the spread of the infection.

The PCR|ONE project is part of the global fight against bacterial resistance to antibiotics. WHO predicts that in the 21st century all antibiotics known at the current technological development will become ineffective and all infections or harmless cuts will become potentially fatal.

The PCR|ONE system will position itself in the rapidly growing molecular diagnostics market. This market is projected to have a global value of US\$10.1 billion in 2021, representing an annual growth rate of 9.1% from its current value of US\$6.5 billion.

Studies in the US have shown that 70% of bacterial strains associated with hospital-acquired infections show resistance to at least one antibiotic previously used to treat conditions caused by the bacterium. Some microorganisms are resistant to all available antibiotics and can only be combated with experimental and often potentially toxic drugs. Wound infections, tuberculosis, pneumonia, sepsis, ear infections, urinary tract infections are already becoming difficult to treat.

In comparison with patients who were treated without consultation, a group of patients with infections (including *Staphylococcus aureus*) who were consulted by a team of antibiotic specialists (microbiologist, infectious disease physician) helped establish:

- reduced length of hospitalisation (5-7 days instead of 9 days),
- a reduction in the therapeutic failure rate (15% instead of 28%),
- an increase in the percentage of optimal treatments (87% instead of 47%),
- a decrease in mortality rates from 8.3% to 6.6%, - a decrease in medical expenses by 15-50%.

One of the main options to counteract widespread bacterial resistance to antibiotics is to combat their overuse. A solution to this problem is universal diagnostics in a fast and effective PoC (Point of Care) format.

The PCR|ONE system consists of a device (analyser) and a disposable panel (microfluidic chip). Until the date of this Information Document, the following milestones have been reached in the development of the system:

- (a) a concept of the device and the disposable microfluidic chip was developed,
- (b) two generations of the device have been developed,
- (c) work on optimising the chip and developing biochemical methods has been completed,
- (d) readiness for industrialisation of the system has been achieved,
- (e) a patent has been obtained in the USA for the invention which is the key technology for the operation of the PCR|ONE system,
- (f) a *Clostridium difficile* panel has been developed,
- (g) an agreement was signed with a transaction advisor for the commercialisation of the PCR|ONE system,
- (h) prevalidation of the PCR|ONE system in the microbiology laboratory of ALAB laboratories,
- (i) readiness of the system for pre-registration testing has been achieved,

(j) information has been received about the decision that a European patent has been obtained for an invention representing key technology for the operation of the PCR-ONE system

(k) results of the second round of the system's prevalidation tests in ALAB laboratories have been received,

(l) a production line for the PCR-ONE system has been launched

(m) pre-registration testing (system verification and validation) necessary for registration and certification of the PCR-ONE system - MRSA/SA panel has started

Until 31 March 2020, expenditure on the system amounted to approximately PLN 19 mln.

In December 2016, Curiosity Diagnostics submitted an application to NCBiR for a grant in the so-called "fast track" programme in the amount of PLN 5.62 mln. In March 2017, the application was accepted.

The Company is currently developing three panels: (i) MRSA (*Methicillin-resistant Staphylococcus aureus*) (ii) *Clostridium difficile* and (iii) *Covid-19*.

MRSA-PCR|ONE panel

It is estimated that from 10 to 50% of the population are constant or periodic carriers of *Staphylococcus aureus*. *Staphylococcus aureus* is a conditionally pathogenic bacterium which causes infections only in favourable conditions, such as decreased immunity, disruption of tissue continuity or a simultaneous presence of other diseases. In hospitals, it is responsible for purulent infections of the skin and subcutaneous tissues and postoperative wound infections. For this reason, antibiotics are given prophylactically before planned operations. Since more than 90% of *Staphylococcus aureus* strains isolated from hospitalised patients are insensitive to penicillins, methicillin is administered and, in the case of MRSA, vancomycin is the antibiotic of last resort. Using an ineffective antibiotic exposes the patient to an infection with very serious consequences. Staphylococcal infections cause complications in the course of the disease and also prolong the period of hospitalization (on average by 5-10 days), which significantly increases the costs of patient care.

The PCR|ONE system will enable rapid screening for MRSA of all patients admitted to hospital. A rapid detection of the pathogen and its methicillin resistance is essential to implement appropriate treatment and isolate patients to prevent the spread of staphylococcus.

Hospital-acquired infection with *Staphylococcus aureus* is one of the most frequent causes of legal claims for compensation from hospitals. In 2003-2005, as many as 32% of cases were claimed for hospital-acquired infection, most frequently caused by *Staphylococcus aureus* (37% among infection claims) (*J. Palka, W. Truskiewicz, Zakażenia szpitalne jako przyczyna cywilnych roszczeń pacjentów, sprawozdanie z konferencji PZU S.A. -PZU Życie S.A.*). Using screening tests among newly admitted patients is a solution to all the above mentioned problems. The introduction of such tests in the Netherlands, Sweden and Denmark made it possible to eliminate *Staphylococcus aureus* infections from their hospitals, which resulted in significant savings for the health service. In addition, the PCR|ONE system's rapid diagnostic method makes it possible to administer the appropriate antibiotic even in urgent cases, such as post-accident patients. The PCR|ONE MRSA panel will be used to screen all patients admitted to hospital and those undergoing emergency medical interventions.

Clostridium panel - PCR|ONE

As few as 3% of adults are carriers of *Clostridium difficile*. This rate increases dramatically among hospitalised patients, where it ranges from 20% to 40%. The widespread administration of antibiotics in hospitals, particularly broad-spectrum antibiotics, promotes infection by destroying the natural intestinal flora. Spores produced by *Clostridium difficile* are insensitive to alcohol antiseptics and most hospital disinfectants, which

promotes patient-to-patient transmission. Clostridium difficile infections cause a wide range of symptoms, from diarrhoea to severe enteritis. In as many as 37% of cases, the infection is severe or complicated, even fatal, especially with the hypervirulent NAP1 strain. Infection with this strain causes death in 16.7% of patients treated in intensive care units.

Due to the ease of transmission of Clostridium difficile infection and the high sporadic survival rate, isolation of patients is the best prophylactic solution. This requires widespread use of a rapid and accurate diagnostic method, such as the PCR-ONE system. It allows immediate treatment and isolation of patients (a significant reduction of Clostridium difficile-associated nosocomial infections), identification of the type of toxin produced by the bacterium, and detection of the most dangerous NAP1 strain (implementation of personalized therapy). For the hospital, this will bring tangible financial benefits due to a significant reduction in hospitalisation (5-10 days on average). The billing settlement system between the hospital and the central health care financing institution (e.g. in Poland) motivates hospitals to cure patients as soon as possible, as they receive an amount depending on the disease unit and not on the time of treatment. Effective prevention of nosocomial infections, which prolong hospitalisation times and increase costs, is therefore economically efficient for hospitals. The Clostridium panel of the PCR|ONE system will be used to screen all patients showing symptoms that may indicate Clostridium difficile infection.

Covid-19 panel - PCR|ONE

On 13 March 2020, the Issuer's Management Board decided to expand the development of the panel for diagnosis of viral respiratory infections to include the development of an ultra-rapid test for detection of SARS-CoV-2 virus, which causes Covid-19 disease. The Company reported on this in its report No. 9/2020.

Further to its report No. 22/2019 on the conditional expansion of Scope Fluidics' project development model, given the announcement of the Covid-19 pandemic and the increasing demand for the detection of potentially pandemic viral infections in the future, the Management Board considered it appropriate to prioritise the expansion of the PCR|ONE product portfolio and extend it to the detection of SARS-CoV-2 virus, which causes Covid-19 disease.

These activities will be undertaken as part of the work to expand the portfolio of PCR|ONE diagnostic assays and will include bioinformatics work, development of a method to isolate genetic material, and optimisation of the sample purification procedure for extraction of genetic material from throat swabs.

The above-mentioned activities will be carried out using the financial resources held by the Company. In the opinion of the Management Board, completion of the above work may increase the business attractiveness of the PCR|ONE system. The Company is analysing the possibilities of obtaining financing for the certification and implementation of the production of SARS-CoV-2 detection tests, including from European Union funds supporting the development of modern technologies and healthcare.

BACTEROMIC System

The vision to develop the BACTEROMIC system crystallized in early 2016. Through consultation with clinicians and on the basis of literature data, we assessed that a system for automated and uniquely comprehensive assessment of antibiotic susceptibility of pathogenic bacteria addresses a very important societal need in global healthcare and enables a significant advantage over the competition, resulting in the development of a compelling product for a market worth approximately USD 1 billion per year (worldwide).

The discovery and introduction of antibiotics was the greatest revolution in the history of medicine. Since the introduction of penicillin in the 1940s, antibiotics have virtually erased the fear of bacterial infections from our consciousness. Indeed, all interventional medicine is made possible by the effective action of antibiotics: from simple infected cuts to surgery, transplantation or immunosuppressive treatment.

Our civilisation has become enamoured with the effectiveness of antibiotics. After the great initial success of penicillin, streptomycin, chloramphenicol, erythromycin, tetracycline, vancomycin, methicillin, ampicillin and cephalosporins, the pharmaceutical industry stopped introducing new antibiotics for several decades. Also, the effectiveness of first-in-class antibiotics resulted in little emphasis on the development of diagnostic techniques.

Unfortunately, bacteria soon became resistant to antibiotics. In a time span ranging from 2 (for methicillin) to almost 40 years (for vancomycin), bacteria have acquired resistance to virtually all existing antibiotics. This resistance is spreading very rapidly. For example, in China, the discovery of resistance to colistin (an antibiotic of last resort, from the polymyxin group) was highly publicised in early 2016. It was widely used there in pig farms. Now (early 2017) colistin resistance is regularly detected in Poland as well.

Since the 1980s, we have seen an exponential rise in antibiotic resistance and a growing epidemiology of antibiotic resistance. This is a ticking time bomb. With the observed rapidity of the spread of resistant pathogens, the predictions of the WHO, the British government, the US Senate committee or the European Commission speak of up to 10 mln. victims per year (i.e. 1/1000 of the planet's population per year). The number of complicated infections is and will be many times greater, causing significant inconvenience to patients and gigantic costs in the health sector.

To give an idea of the scale of the cost to the economy, in the US alone, the expense resulting from bacterial pathogen resistance is estimated at USD 55 billion per year, including USD 20 billion in direct costs and USD 35 billion in indirect costs, e.g. redundancies, reduced economic activity, compensation, etc.

Development of new antibiotics is to be expected, but new substances cannot be expected to provide a solution to the problem over the next 10-20 years. All expert groups and reports on the problem of antibiotic resistance indicate that the most important direction in the fight against antibiotic-resistant bacteria is the development of diagnostic technologies. It is well known that targeted therapies, i.e. the use of antibiotics selected on the basis of knowledge about the susceptibility of bacteria, are up to twice as effective as empirical therapies, taking into account the length of hospitalisation, the number of recurrences and the cost of treatment. Over 70% of antibiotics are prescribed unnecessarily or are ineffective. Even if new drugs are introduced in the next few decades, it is to be expected that the emphasis and investment in detailed diagnostics will remain very high. This will be the only way to maintain the effectiveness of antibiotics.

Medicine needs diagnostic systems that can identify a bacterial pathogen in the shortest possible time and as economically as possible, and determine its sensitivity (or resistance) to the widest possible range of available antibiotics and, where they exist, the type and mechanism of resistance to a given antibiotic or a given group of antibiotics. The BACTEROMIC system concept responds to the needs identified above.

Demand for such diagnostic solutions is driven by:

- a general trend towards dissemination of targeted therapies based on detailed knowledge of drug susceptibility of the bacteria causing the infection;
- the lack of other life-saving options in the case of infection with strains resistant to most available antibiotics,
- preparation for gradual introduction of antibiotic combinations for use in the case of infections in which no single-administered antibiotics are effective.

Until the date of this Information Document, the following milestones have been reached in the development of the system:

- a) a solution concept that will enable construction of the groundbreaking BACTEROMIC system,
- b) documentation of the system concept including: description of the system functionalities, description of the recommended technical solutions, preliminary market analysis, preliminary analysis for building a patent protection portfolio, and preliminary analysis for the system registration procedure,

- c) development of the system architecture,
- d) completion of the design of a prototype device, a panel and a pilot line for filling and closing the panels,
- e) launch of a prototype and pilot F&S (filling and sealing) line,
- f) completion of first tests of the BACTEROMIC system at the National Institute of Medicines,
- g) validation of a prototype and a pilot F&S line
- h) completion of tests of the BACTEROMIC system at the Pulmonary Tuberculosis Institute in Warsaw, i) obtaining of readiness for industrialisation of the system and development of the design of the F&S line, j) obtaining of readiness for pre-registration tests.

Until 31 March 2020, expenditure on the system amounted to approximately PLN 6.5 mln.

In December 2016, the Issuer was informed of the positive outcome of a contest and awarding of a grant of PLN 1.5 mln. In October 2019, the Issuer's subsidiary Bacteromic Sp. z o.o. signed an agreement with The Executive Agency for Small and Medium-sized Enterprises (EASME) for a grant of EUR 1.927 million for the BACTEROMIC project. This amount will cover 70% of eligible costs necessary to complete the project.

12.3. Brief presentation of the Issuer's shareholders holding at least 5% of the votes at the General Meeting

The shareholder structure of the Issuer as of the date of the Information Document is as follows:

Table 1. Shareholder structure of Scope Fluidics S.A. as of the date of the Information Document

Shareholder structure	Number of shares	% of the share capital	Number of votes	% of votes at GM
TOTAL FIZ (including subsidiaries)	668,449	26.13%	668,449	26.13%
Piotr Garstecki	374,924	14.65%	374,924	14.65%
Marcin Izydorzak	366,355	14.32%	366,355	14.32%
Esaliens TFI S.A	161,105	6.30%	161,105	6.30%
Other shareholders (below 5% of votes at GM)	987,457	38.60%	987,457	38.60%
Total	2,558,290	100%	2,558,290	100%

Source: Issuer

13. Additional information, including the amount of share capital and indication of the Issuer's corporate documents available for inspection

The Issuer's share capital as of the day of preparing this Information Document is PLN 255,829 (two hundred and fifty-five thousand eight hundred and twenty-nine zloty) and is divided into: 2,558,290 (two million five

hundred and fifty-eight thousand two hundred and ninety) shares with a nominal value of PLN 0.10 (ten grosz) each, including:

- 101,107 registered series A,
- 1,268,893 Series B ordinary bearer shares,
- 900,000 Series B ordinary bearer shares,
- 34,050 Series D ordinary bearer shares,
- 11,350 Series E ordinary bearer shares,
- 231,540 Series F ordinary bearer shares,
- 11,350 Series G ordinary registered shares.

The Issuer's share capital is fully paid up.

On 16 December 2019, the Company's Management Board submitted a statement on the amount of the subscribed share capital and on adjustment of the share capital in the Articles of Association in connection with the completed subscription of series F shares issued pursuant to Resolution No. 3 of the Extraordinary General Meeting of 10 December 2019 on increase of the Company's share capital through issuance of series F shares by way of private subscription with complete exclusion of the preemptive rights of existing shareholders, dematerialisation and introduction to trading in the Alternative Trading System on the NewConnect market operated by the Warsaw Stock Exchange, and amendment to the Articles of Association.

The Company's Management Board stated that the Company's share capital was increased by the amount of PLN 23,154 through the issuance of 231,540 series F ordinary bearer shares with a nominal value of PLN 0.10 per share. In connection with the above, the Management Board adjusted the amount of the share capital in the Company's Articles of Association by giving § 4 (1) and (2) the following wording:

1. The Company's share capital is PLN 254,694 (two hundred and fifty-four thousand six hundred and ninety-four zloty) and is divided into 2,546,940 (two million five hundred and forty-six thousand nine hundred and forty) shares, with a nominal value of PLN 0.1 (ten groszy) per share.
2. The share capital shall be composed of:
 - 1) series A registered shares in the number of 101,107 (one hundred and one thousand one hundred and seven) numbered 1213286 to 1314392 with the total value of PLN 10,110.70 (ten thousand one hundred and ten zlotys and seventy grosz).
 - 2) series B bearer shares in the number of 1,268,893 (one million two hundred sixty eight thousand eight hundred ninety three) numbered from 0000001 to 1268893 with the total value of PLN 126,889.30 (one hundred twenty six thousand eight hundred eighty nine zloty thirty grosz).
 - 3) 900,000 (nine hundred thousand) series C ordinary bearer shares with consecutive numbers from 000001 to 900000.
 - 4) 34,050 (thirty four thousand and fifty) series D ordinary registered shares with consecutive numbers from 00001 to 34050.
 - 5) 11,350 (eleven thousand three hundred and fifty) series E ordinary registered shares with consecutive numbers from 00001 to 11350.

- 6) 231,540 (two hundred and thirty-one thousand five hundred and forty) series F ordinary bearer shares with consecutive numbers from 000001 to 231540.

On 16 December 2019, the Supervisory Board adopted a resolution on adoption of the consolidated text of the Issuer's Articles of Association.

The amendment to the Articles of Association was registered with the National Court Register on 2 January 2020.

Information about the Issuer together with corporate documents can be found on the Issuer's website under the tab investor relations.

13a. A statement by the Issuer to the effect that, in its opinion, the level of working capital is sufficient to meet its needs for the period of 12 months from the date of the information document and, if not, a proposal for the provision of additional working capital.

The Issuer represents that, in its opinion, the level of working capital is sufficient to cover its needs for the 12 months from the date of the Information Document.

13b. Information on projected changes in the share capital as a result of bondholders exercising their rights under convertible bonds or bonds giving priority to new share issues in the future, or as a result of exercising their rights by holders of subscription warrants, with an indication of the value of the projected conditional share capital increase and the date of expiry of the rights of entities authorised to acquire those shares

As of the date of the Information Document, the Issuer does not have any liabilities arising from the issue of bonds convertible into shares, bonds giving preference to subscribe for new issues of shares in the future or from the exercise of rights by holders of subscription warrants, and therefore at present there are no grounds to anticipate any changes in the share capital under the conditional share capital increase as a result of the exercise of such rights.

13c. Indication of the number of shares and the value of the share capital by which, *on the basis of the Articles of Association providing for authorisation by the Management Board to increase the share capital within the limits of the authorised capital, the share capital may be increased, as well as of the number of shares and the value of the share capital by which the share capital may still be increased in this manner

Pursuant to § 7 (1) of the Articles of Association, the Management Board is authorised to issue up to 70,000 subscription warrants, registered or bearer, entitling the holder thereof to subscribe for the new shares referred to in § 7 (5) of the Articles of Association ("New Shares"), excluding subscription rights ("Subscription Warrants").

Pursuant to § 7 (5) of the Articles of Association, the Management Board is authorised to increase the Issuer's share capital by issuing new ordinary registered shares of successive series with a nominal value of PLN 0.10 each, in an amount not exceeding 3.5% of the value of the share capital as of the date of the increase and at the same time no more than 70,000 shares and the total nominal value of all the new shares not exceeding PLN 7,000.00, by way of one or several increases of the share capital (authorised capital). The Management Board's authorisation to increase the share capital within the authorised capital expires 3 years from the date on which the Company was entered in the Register of Entrepreneurs of the National Court Register (i.e. 3 years from 27 March 2017).

Each Subscription Warrant shall entitle the holder to subscribe for one New Share. The New Shares shall be

taken up in a private subscription. The Management Board may issue New Shares in exchange for contributions in cash or in kind.

All matters relating to the issue of the Subscription Warrants and to the increase of the share capital within the limits of the authorised capital shall be decided by the Management Board.

On 11 October 2017, the Company's Management Board adopted a resolution on the issue of 34,050 (thirty-four thousand and fifty) series A registered subscription warrants. Information on the issue of series A subscription warrants was made public in the Issuer's reports No. 9/2017 and 10/2017.

On 2 October 2018, the Company's Management Board adopted a resolution to issue 11,350 (eleven thousand three hundred and fifty) Series B registered subscription warrants. Information on the issue of series B subscription warrants was made public in the Issuer's report No. 12/2018.

On 19 February 2020, the Company's Management Board adopted a resolution to issue 11,350 series C subscription warrants. Information on the issue of series C subscription warrants was made public in the Issuer's report No. 4/2020.

14. Indication of the place of access

14.1. The last public information document or information document made available to the public for these financial instruments or for financial instruments of the same type as these financial instruments

The last publicly available public information document for financial instruments of the same type as these financial instruments is available on the Issuer's website (investor relations tab): <http://scopefluidics.com/relacje-inwestorskie/>.

14.2. The Issuer's periodic financial reports published under the law applicable to the Issuer

The Issuer's periodic financial reports are made public through the Electronic Information Base (EBI) system and are available on the NewConnect market website <http://www.newconnect.pl> and on the Issuer's website (investor relations tab): <http://scopefluidics.com/relacje-inwestorskie/>.

APPENDICES

Appendix 1 - Current excerpt from the National Court Register (KRS)

Page1 of 9

Excerpt of information derived pursuant to Article 4 (4aa) of the Act on the National Court Register of 20 August 1997, has same legal effect as a document issued by the Central Intelligence Branch, requires no signature or seal.

CENTRAL INTELLIGENCE BRANCH OF THE NATIONAL COURT REGISTER

NATIONAL COURT REGISTER

Status on 08.04.2020 godz. 14:16:34

KRS Number: 0000668408

This information is equivalent to the up-to-date excerpt
FROM THE REGISTER OF ENTREPRENEURS

Date of registration with the National Court Register on		27.03.2017		
Last entry	Entry Number	24	Date of entry	07.04.2020
	File Ref. No.	WA.X11 NS-REJ.KRS/21678/20/148		
	Court of registration	DISTRICT COURT FOR THE CAPITAL OF WARSAW IN WARSAW, XII COMMERCIAL DIVISION OF THE NATIONAL COURT REGISTER		

Section 1

Rubric 1 - Data on entity	
1. Legal status	JOINT-STOCK COMPANY
2. REGON/NIP code:	REGON: 142754170, NIP number: 5272645989
3. Registered business name of company	SCOPE FLUIDICS SPÓŁKA AKCYJNA
4. Data on previous registration	—
5. Does the entrepreneur conduct business activity with other business entities pursuant to a civil law partnership agreement?	NO
6. Does the entrepreneur have the status of a public benefit organization?	NO

Rubric 2 - Registered office and address of entity	
1. Registered office	country POLAND, voivodeship MAZOWIECKIE, powiat, gmina WARSAW, town WARSAW WARSAW
2. Address	ul. DUCHNICKA, NO 3, BUILDING 16, Apartment ENTRANCE A, town Warsaw, post code 01-796, post code Warsaw, country POLAND
3. E-mail address	BIURO@SCOPEFLUIDICS.COM
4. Website address	WWW.SCOPEFLUIDICS.COM

Rubric 3 - Branches

No entry

Rubric 4 - Information on the Articles of Association

1. Information on the execution of, or amendments to, the Articles of Association	1	06.03.2017 R., ROLL OF DEEDS 1468/2017, CIVIL-LAW NOTARY KAMILA KALIŃSKA OF CIVIL-LAW NOTARY OFFICE IN WARSAW AT UL. DERENIOWA 2 APARTMENT 97
	2	29.03.2017, ROLL OF DEEDS 2072/2017, CIVIL-LAW NOTARY KAMILA KALIŃSKA OF CIVIL-LAW NOTARY

	OFFICE IN WARSAW, AMENDMENTS MADE TO: §4 (1) AND (2) ARTICLES OF ASSOCIATION
3	16.10.2017, ROLL OF DEEDS 5774/2017, CIVIL-LAW NOTARY DANIEL NESTOROWICZ, CIVIL-LAW NOTARY'S OFFICE IN WARSAW, AMENDMENTS MADE TO: § 4 (1) AND (2)
4	19.11.2018 ROLL OF DEEDS 254/2018, CIVIL-LAW NOTARY DANIEL NESTOROWICZ, CIVIL-LAW NOTARY'S OFFICE IN WARSAW, AMENDMENTS MADE TO: § 4 (1) AND (2)
5	10.12.2019, ROLL OF DEEDS 303/2019, CIVIL-LAW NOTARY DANIEL NESTOROWICZ, CIVIL-LAW NOTARY'S OFFICE IN WARSAW, AMENDMENTS MADE TO: § 4 (1) AND (2) ARTICLES OF ASSOCIATION 16.12.2019, ROLL OF DEEDS 334/2019, CIVIL-LAW NOTARY EWA SZMAGALSKA, CIVIL-LAW NOTARY'S OFFICE IN WARSAW, AMENDMENTS MADE TO: § 4 (1) AND (2) ARTICLES OF ASSOCIATION
6	25.03.2020, ROLL OF DEEDS 403/2020, CIVIL-LAW NOTARY DANIEL NESTOROWICZ, CIVIL-LAW NOTARY'S OFFICE IN WARSAW, AMENDMENTS MADE TO: § 4 (1) AND (2) ARTICLES OF ASSOCIATION 25.03.2020, ROLL OF DEEDS 403/2020, CIVIL-LAW NOTARY DANIEL NESTOROWICZ, CIVIL-LAW NOTARY'S OFFICE IN WARSAW, MANAGEMENT BOARD DECLARATION ON SHARE CAPITAL INCREASE, DETERMINATION OF THE CONSOLIDATED TEXT;

Rubric 5

1. Time period for which the company was established	UNDEFINED
2. Name of the gazette selected for publication of company announcements other than Monitor Sądowy i Gospodarczy (Court and Commercial Gazette)	-----
4. Does the Articles of Association provide certain shareholders with personal rights or titles to participate in the company's profits which do not arise from share ownership?	YES
5. Do bondholders have the right to participate in the company's profit?	NO

Rubric 6 - Method of establishing the company

1. Description of circumstances of company establishment	TRANSFORMATION
2. Description of the method of establishment of the Company and information about the resolution	TRANSFORMATION OF SCOPE FLUIDICS SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ WITH ITS WITH ITS PRINCIPAL PLACE OF BUSINESS IN WARSAW INTO SCOPE FLUIDICS SPÓŁKA AKCYJNA BASED ON RESOLUTION NO. 2 OF THE EXTRAORDINARY SHAREHOLDERS MEETING OF SCOPE FLUIDICS SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ OF 03 FEBRUARY 2017 REFERENCED BY NOTARIAL DEED ROLL OF DEEDS 690/2017 BY CIVIL-LAW NOTARY KAMILA KALIŃSKA OF CIVIL-LAW NOTARY OFFICE IN WARSAW

3. Number and date of the decision of the President of the Office of Competition and Consumer Protection concerning a consent to the consolidation	-----
--	-------

Sub-Rubric 1 Entities which formed the company

1	1. Name or company	SCOPE FLUIDICS SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ, -----
	2. Country and name of the register in which the business entity was entered	NATIONAL COURT REGISTER
	3. Register or record number	0000375116
	4. Name of the court keeping the register	*****
	5. REGON number	142754170
	6. NIP (Tax ID) number	5272645989

Rubric 7 - Information on sole shareholder No entry
--

Rubric 8 - The company's equity
--

1. Authorized share capital	PLN 255 829,00
2. Maximum authorized share capital	PLN 7 000,00
3. Number of shares of all issues	2,558,290
4. Nominal value of a share	PLN 0.10
5. Amount of paid-in capital	PLN 255,829.00
6. Nominal value of conditional increase of share capital	-----

Sub-Rubric 1 Information regarding contribution in kind
--

No entry

Rubric 9 - Issue of shares

1	1. Share series designation	SERIES A SHARES
	2. Number of shares in series	101,107
	3. Type of preference of shares and number of preference shares or statement that the shares are not preference shares	THE SHARES ARE NOT PREFERENCE SHARES
2	1. Share series designation	SERIES B SHARES
	2. Number of shares in series	1,268,893
	3. Type of preference of shares and number of preference shares or statement that the shares are not preference shares	THE SHARES ARE NOT PREFERENCE SHARES

3	1.Share series designation	SERIES C SHARES
	2.Number of shares in series	900,000
	3.Type of preference of shares and number of preference shares	THE SHARES ARE NOT PREFERENCE SHARES
	THE SHARES ARE NOT PREFERENCE SHARES	
4	1.Share series designation	D
	2.Number of shares in series	34,050
	3.Type of preference of shares and number of preference shares or statement that the shares are not preference shares	THE SHARES ARE NOT PREFERENCE SHARES
5	1.Share series designation	E
	2.Number of shares in series	11,350
	3.Type of preference of shares and number of preference shares or statement that the shares are not preference shares	THE SHARES ARE NOT PREFERENCE SHARES
6	1.Share series designation	SERIES F SHARES
	2.Number of shares in series	231,540
	3.Type of preference of shares and number of preference shares or statement that the shares are not preference shares	THE SHARES ARE NOT PREFERENCE SHARES
7	1.Share series designation	SERIES G SHARES
	2.Number of shares in series	11,350
	3.Type of preference of shares and number of preference shares or statement that the shares are not preference shares	THE SHARES ARE NOT PREFERENCE SHARES

Rubric 10 - Note on resolution to issue convertible bonds

No entry

Rubric 11

1.Do the management board or administrative council have the right to issue subscription warrants?	YES
--	-----

Section 2

Rubric 1 - Directing body authorized to represent this business entity

1.Designation of the directing body authorized to represent this business entity	MANAGEMENT BOARD
2.Manner of representation	THE COMPANY IS REPRESENTED BY TWO MANAGEMENT BOARD MEMBERS ACTING JOINTLY OR BY ONE BOARD MEMBER TOGETHER WITH A POWER OF PROCURATION HOLDER

Sub-Rubric 1

Information on persons serving as members of the supervising body

1	1.Person's / Company's name	GARSTECKI
	2.First name(s)	PIOTR
	3.PESEL/REGON number	75100800830
	4.KRS Number	****
	5.Function assigned in directing body	PRESIDENT OF THE MANAGEMENT BOARD
	6.Has the person serving as member of the management board been suspended in his/her functions?	NO
	7. End date of suspension	—
2	1.Person's / Company's name	IZYDORZAK
	2.First name(s)	MARCIN
	3.PESEL/REGON number	74042500633
	4.KRS Number	****
	5.Function assigned in directing body	MEMBER OF THE MANAGEMENT BOARD
	6.Has the person serving as member of the management board been suspended in his/her functions?	NO
	7. End date of suspension	—
3	1.Person's / Company's name	RUTA
	2.First name(s)	SZYMON MICHAŁ
	3.PESEL/REGON number	75112801939
	4.KRS Number	****
	5.Function assigned in directing body	MEMBER OF THE MANAGEMENT BOARD
	6.Has the person serving as member of the management board been suspended in his/her functions?	NO
	7. End date of suspension	—

Rubric 2 - Supervising Body

1.Designation of the Supervising Body		SUPERVISORY BOARD
<p>Sub-Rubric 1</p> <p>Information on persons serving as members of the supervising body</p>		
1	1.Last name	HOLYST
	2.First name(s)	ROBERT PIOTR
	3.PESEL number	63012202550
2	1.Last name	PRZYTUŁA
	2.First name(s)	ROBERT BOGUSŁAW
	3.PESEL number	74121708170

3	1.Last name	CHĄDZYŃSKI
	2.First name(s)	ANDRZEJ
	3.PESEL number	76012000035
4	1.Last name	MIKUCKI
	2.First name(s)	PATRYK
	3.PESEL number	75031203977

Rubric 3 - Commercial Proxies No entry Section 3

Rubric 1 - Statement of company's objects		
1.Entrepreneur's prime objects	1	72.19.Z OTHER RESEARCH AND EXPERIMENTAL DEVELOPMENT IN NATURAL SCIENCES AND ENGINEERING
2.Entrepreneur's subsidiary objects	1	22, 29, Z, MANUFACTURE OF OTHER PLASTIC PRODUCTS
	2	74, 10, Z, SPECIALISED DESIGN ACTIVITIES
	3	77.40.Z: LEASING OF INTELLECTUAL PROPERTY AND SIMILAR PRODUCTS, EXCEPT FOR COPYRIGHTED WORKS
	4	26, 11, Z MANUFACTURE OF ELECTRONIC COMPONENTS
	5	62, 01, Z, SOFTWARE RELATED ACTIVITIES
	6	71, 20, B, OTHER TECHNICAL TESTS AND ANALYSES
	7	71, 12, Z, ACTIVITIES IN ENGINEERING AND RELATED TECHNICAL CONSULTANCY
	8	74, 90, Z, OTHER PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES, NOT CLASSIFIED ELSEWHERE
	9	72.11.Z - SCIENTIFIC RESEARCH AND DEVELOPMENT WORKS IN THE FIELD OF BIOTECHNOLOGY

Rubric 2 - Note on submitted documents

Type of document	Sequence No. in field	Submission date	Covering period from to
1.Note on submitting the annual financial statement	1	22.08.2018	FROM 01.01.2017 TO 31.12.2017
	2	02.08.2019	FROM 01.01.2018 TO 31.12.2018
	3	02.09.2020	FROM 01.01.2019 TO 31.12.2019
	4	07.07.2021	FROM 01.01.2020 TO 31.12.2020
2.Note on submitting the auditor's opinion on the annual financial statement	1	*****	FROM 01.01.2017 TO 31.12.2017
	2	*****	FROM 01.01.2018 TO 31.12.2018
	3	*****	FROM 01.01.2019 TO 31.12.2019
	4	*****	FROM 01.01.2020 TO 31.12.2020
1.3. Information on submission of resolution or decision on approval of the annual financial statement	1	*****	FROM 01.01.2017 TO 31.12.2017
	2	*****	FROM 01.01.2018 TO 31.12.2018

	3	*****	FROM 01.01.2019 TO 31.12.2019
	4	*****	FROM 01.01.2020 TO 31.12.2020
4. Note on submission of the report on the business entity's operations	1	*****	FROM 01.01.2017 TO 31.12.2017
	2	*****	FROM 01.01.2018 TO 31.12.2018

Rubric 3 - Capital Group's reports

Type of document	Sequence No. in field	Submission date	Covering period from to
1. Note on submitting the annual financial statement	1	22.08.2018	FROM 01.01.2017 TO 31.12.2017
	2	02.08.2019	FROM 01.01.2018 TO 31.12.2018
2. Note on submitting the opinion of the certified auditor / audit report on the annual consolidated financial statements	1	*****	FROM 01.01.2017 TO 31.12.2017
	2	*****	FROM 01.01.2018 TO 31.12.2018
3. Note on the submission of a resolution or a decision regarding an approval of the annual financial statement	1	*****	FROM 01.01.2017 TO 31.12.2017
	2	*****	FROM 01.01.2018 TO 31.12.2018
4. Note on submission of the report on the business entity's operations	1	*****	FROM 01.01.2017 TO 31.12.2017
	2	*****	FROM 01.01.2018 TO 31.12.2018

Rubric 4 - Object of statutory business of public benefit organization

No entry

Rubric 5 - Information on fiscal year closing date

1. Date closing the first financial year for which financial statements are to be submitted	31.12.2017
---	------------

Section 4

Rubric 1 - Delinquent payments

No entry

Rubric 2 - Liabilities

No entry

Rubric 3 - Information on dismissal of bankruptcy petition pursuant to Article 13 of the 28 February 2003 Act on Bankruptcy Law or on securing the debtor's assets in bankruptcy proceedings or in restructuring proceedings, or after final discontinuance of the restructuring proceedings

No entry

Rubric 4 - Discontinuance of enforcement proceedings against the subject of enforced collection because the enforcement will not yield an amount exceeding the costs of enforced collection

No entry

Section 5

Rubric 1 - Court-appointed administrator

No entry

Section 6

Rubric 1 - Liquidation

No entry

Rubric 2 - Information on dissolution or invalidation of the business entity

No entry

Rubric 3 - Mandatory administration

No entry

Rubric 4 - Information on merger, division or reconstruction

No entry

Rubric 5 - Information on bankruptcy proceedings

No entry

Rubric 6 - Information on arrangement proceedings

No entry

Rubric 7 - Information on restructuring proceedings, recovery proceedings or mandatory restructuring

No entry

Rubric 8 - Information on suspension of business operations

No entry

date prepared 14.04.2020

address of the website containing the information from the National Court Register: ekrs.ms.gov.pl

Appendix 2 - Articles of Association

ARTICLES OF ASSOCIATION OF SCOPE FLUIDICS

SPÓŁKA AKCYJNA

General provisions

§1

1. The Appearing Parties, hereinafter referred to as Shareholders, represent, that they are establishing a joint stock company, hereinafter referred to as the "Company".
2. The company operates under the name: Scope Fluidics Spółka Akcyjna. The company may use the abbreviated name Scope Fluidics S.A. and its distinguishing graphic sign (logo).
3. The Company's principal place of business is the capital city of Warsaw.
4. The Company may establish its branches in the Republic of Poland and abroad.
5. The Company was established as a result of transformation of the company "SCOPE FLUIDICS" Sp. z o.o. z/s in Warsaw entered in the Register of Entrepreneurs of the National Court Register under number 0000375116.

The Company's Objects

§ 2

1. The Company's line of business is as follows:
 - 1) 72.11.Z - Scientific research and development works in the field of biotechnology;
 - 2) 71, 20, B, Other technical testing and analysis;
 - 3) 71.12.Z Engineering activities and related technical consultancy;
 - 4) 72.19.Z Other research and experimental development in natural sciences and engineering
 - 5) 74.10.Z Specialised design activities;
 - 6) 74.90.Z Other professional, scientific and technical activities not elsewhere classified;
 - 7) 77.39.Z Renting and leasing of other machinery, equipment and tangible goods not classified elsewhere;
 - 8) 77.40.Z Leasing of intellectual property and similar products, excluding works protected by copyright;
 - 9) 71.20.B Other technical testing and analysis;
 - 10) 18.12.Z Other printing;
 - 11) 18.13.Z Service activities related to the preparation of printing;
 - 12) 18.20.Z Reproduction of recorded media;
 - 13) 20.20.Z Manufacture of pesticides and other agrochemical products;
 - 14) 20.59.Z Manufacture of other chemical products not classified elsewhere;
 - 15) 21.20.Z Manufacture of medicines and other pharmaceutical products;
 - 16) 22.19.Z Manufacture of other rubber products;
 - 17) 22.22.Z Manufacture of plastic packaging;
 - 18) 22.23.Z Manufacture of plastic building products;
 - 19) 22.29.Z Manufacture of other plastic products;
 - 20) 26.11.Z Manufacture of electronic components;
 - 21) 26.20.Z Manufacture of computers and peripheral equipment
 - 22) 25.91.Z Manufacture of metal containers;
 - 23) 25.99.Z Manufacture of other fabricated metal products not classified elsewhere;
 - 24) 26.12.Z Manufacture of electronic printed circuit boards;
 - 25) 32.50.Z Manufacture of medical and dental instruments and supplies;
 - 26) 33.11.Z Repair and maintenance of fabricated metal products;
 - 27) 33.12.Z Repair and maintenance of machinery;
 - 28) 33.13.Z Repair and maintenance of electronic and optical devices;
 - 29) 33.14.Z Repair and maintenance of electrical equipment;
 - 30) 33.20.Z Installation of industrial machinery, equipment and supplies;
 - 31) 46.90.Z Non-specialised wholesale trade;
 - 32) 47.91.Z Retail sale via mail order houses or via Internet;

- 33) 47.99.Z Other retail sale conducted outside shopping chains, stalls and markets;
 - 34) 58.11.Z Publishing of books;
 - 35) 58.19.Z Other publishing activities;
 - 36) 58.29.Z Publishing of other software;
 - 37) 68.10.Z Buying and selling of own real estate
 - 38) 68.20.Z Rental and management of own or leased real estate;
 - 39) 62.01.Z Activities related to software;
 - 40) 62.02.Z Computer consultancy activities;
 - 41) 62.03.Z Computer facilities management activities;
 - 42) 62.09.Z Other information technology and computer service activities;
 - 43) 63.11.Z Data processing, hosting and related activities;
 - 44) 63.12.Z Activities of web portals,
 - 45) 63.99.Z Other information service activities not classified elsewhere;
 - 46) 70.22.Z Other business and management consulting;
 - 47) 71.20.A Research and analysis related to food quality,
 - 48) 85.59.B Other education not elsewhere classified;
 - 49) 85.60.Z Activities supporting education.
 - 50) 70.10.Z Activities of head offices and holdings (excluding financial holdings);
2. Business operations may be conducted by the Company on its own account and on the basis of orders from third parties.
 3. If the commencement of any activity in any respect requires a licence or other authorisation, the Company shall obtain such licence or authorisation before commencing the activity.
 4. If the commencement of any activity in any respect requires suitably documented qualifications of the persons carrying on or supervising that activity, the Company is required to comply with this requirement before commencing the activity.

Duration of the Company

§3

The Company shall have perpetual existence.

Share capital

§ 4

1. The Company's share capital is PLN 255,829 (two hundred and fifty five thousand eight hundred and twenty nine zloty) and is divided into: 2,558,290 (two million five hundred and fifty-eight thousand two hundred and ninety) shares, with a nominal value of PLN 0.1 (ten grosz) per share.
2. The share capital shall be composed of:
 - 1) series A registered shares in the number of 101,107 (one hundred and one thousand one hundred and seven) numbered 1213286 to 1314392 with the total value of PLN 10,110.70 (ten thousand one hundred and ten zlotys and seventy grosz).
 - 2) series B bearer shares in the number of 1,268,893 (one million two hundred sixty eight thousand eight hundred ninety three) numbered from 0000001 to 1268893 with the total value of PLN 126,889.30 (one hundred twenty six thousand eight hundred eighty nine zloty thirty grosz).
 - 3) 900,000 (nine hundred thousand) series C ordinary bearer shares with consecutive numbers from 000001 to 900000.
 - 4) 34,050 (thirty four thousand and fifty) series D ordinary registered shares with consecutive numbers from 00001 to 34050.
 - 5) 11,350 (eleven thousand three hundred and fifty) series E ordinary registered shares with consecutive numbers from 00001 to 11350.
 - 6) 231,540 (two hundred and thirty-one thousand five hundred and forty) series F ordinary bearer shares with consecutive numbers from 000001 to 231540.
 - 7) 11,350 (eleven thousand three hundred and fifty) series G ordinary registered shares with consecutive numbers from 00001 to 11350.
3. On the incorporation of the Company, the shares were subscribed for by the founders of the Company as follows:

- 1) Total Fundusz Inwestycyjny Zamknięty, with its principal place of business in Warsaw, NIP 1080007268, took up 478,236 (four hundred and seventy-eight thousand, two hundred and thirty-six) shares with a nominal value of PLN 0.1 (ten grosz) each, numbered from 0000001 to 0478236 and a total nominal value of PLN 47,823.60 (forty-seven thousand, eight hundred and twenty-three zloty and sixty grosz);
 - 2) Piotr Garstecki took up 373,591 (three hundred and seventy-three thousand five hundred and ninety-one) shares with a nominal value of PLN 0.1 (ten grosz) each, numbered 0478237 through 0851827, with a total nominal value of PLN 37,359.10 (thirty-seven thousand three hundred and fifty-nine zloty and ten grosz);
 - 3) Marcin Izydorczak took up 361,458 (three hundred and sixty-one thousand four hundred and fifty-eight) shares with the nominal value of PLN 0.1 (ten groszy) each, numbered from 0851828 to 1213285 and the total nominal value of PLN 36,145.80 (thirty-six thousand one hundred and forty-five zloty and eighty grosz);
 - 4) The Institute of Physical Chemistry of the Polish Academy of Sciences took up 101,107 (one hundred and one thousand one hundred and seven) shares with the nominal value of PLN 0.1 (ten groszy) each, numbered from 1213286 to 1314392 and the total nominal value of PLN 10,110.70 (ten thousand one hundred and ten zloty and seventy grosz);
 - 5) Robert Hołyst took up 40,443 (forty thousand four hundred and forty-three) shares with a nominal value of PLN 0.1 (ten groszy) each, numbered from 1314393 to 1354835 and a total nominal value of PLN 4,044.30 (four thousand forty-four zloty and thirty grosz);
 - 6) Piotr Korczyk took up 5,055 (five thousand and fifty-five) shares with the nominal value of PLN 0.1 (ten groszy) each, numbered from 1354836 to 1359890 and the total nominal value of PLN 505.50 (five hundred and five zloty and fifty grosz);
 - 7) Tomasz Kamiński took up 5,055 (five thousand and fifty-five) shares with the nominal value of PLN 0.1 (ten groszy) each, numbered from 1359891 to 1364945 and the total nominal value of PLN 505.50 (five hundred and five zloty and fifty grosz);
 - 8) Paweł Dębski took up 5,055 (five thousand and fifty-five) shares with the nominal value of PLN 0.1 (ten groszy) each, numbered from 1364946 to 1370000 and the total nominal value of PLN 505.50 (five hundred and five zloty and fifty grosz).
4. Before the Company registration, the share capital was covered by the founders of the Company in its entirety with their shares in the assets of the transformed company "SCOPE FLUIDICS" Sp. z o.o. based in Warsaw, registered in the Register of Entrepreneurs of the National Court Register under number 0000375116.

Share capital increase, issue of shares and debt instruments

§ 5

1. The Company may issue registered shares and bearer shares.
2. The shareholders have a preemptive right to subscribe for shares in the Company's increased share capital, in proportion to the shares held.
3. Registered shares may be converted into bearer shares at the written request of the shareholder concerned. The conversion is carried out by the Management Board within one month from the date of submission of the application by the shareholder.
4. Bearer shares are not convertible into registered shares.
5. The Company may issue debt securities, including, in particular, bonds convertible into shares, as well as bonds with a preemptive right to acquire shares in the Company.
6. The Company may keep a record of the shares in dematerialised form.

Profit-sharing

§ 6

1. The Company's profit shall be distributed by resolution of the General Meeting, subject to the following paragraphs.
2. Subject to mandatory provisions of law, at least a half of the funds received in the financial year by the Company from unrelated parties as a result of the sale of shares, interests, bonds convertible into shares or organised parts of an enterprise shall be set aside for distribution to shareholders. The decision on the

amount of the distribution in excess of half of the funds obtained shall rest with the Management Board and shall depend on the current and anticipated financial position of the Company. The disbursement may be made in the form of a dividend or purchase of own shares. The form of payment shall be determined by resolution of the General Meeting adopted by a simple majority of votes. Total payments to shareholders in a given calendar year may not exceed the amount determined by the decision of the Management Board referred to in this paragraph.

3. A derogation from the rules provided for in Sub-paragraph 2 above requires a resolution of the General Meeting adopted by a two-thirds (2/3) majority.
4. The Company may, by resolution of the General Meeting adopted by a 3/4 (three fourths) majority vote, create capital (funds), including reserve capital (funds) or reserve funds. The decision on liquidation of particular capital (fund) and rules of using it shall be made by the shareholders by resolution creating such capital (fund).
5. The Management Board may make advances to shareholders against expected dividends at the end of the financial year if the Company has sufficient funds to make the payment.

Subscription warrants

§ 7

1. The Management Board shall be authorised to issue no more than 70,000 (seventy thousand) subscription warrants, registered or bearer, entitling the holder thereof to subscribe for the shares referred to in Sub-Paragraph 5 below ("New Shares"), excluding subscription rights ("Subscription Warrants"). The term of exercise of the subscription rights attached to the Subscription Warrants shall expire no later than the period for which the Management Board has been authorised to increase the share capital within the framework of the authorised capital referred to in Sub-paragraph 6 below.
2. The issue price of the Subscription Warrants shall be PLN 0.01 (one grosz) per Subscription Warrant.
3. Each Subscription Warrant shall entitle the holder to subscribe for one New Share.
4. The Management Board shall decide on all matters relating to the issue of the Subscription Warrants, in particular the Management Board shall be authorised to determine:
 - a) the persons entitled to subscribe for the Subscription Warrants, whereby the persons entitled to subscribe for the Subscription Warrants shall be members of the Company's Management Board and other key management personnel of the Company;
 - b) the terms and conditions for exercising the rights attached to the Subscription Warrant,
 - c) the designation of subsequent issues of Subscription Warrants,
 - d) the conditions for the redemption of the Subscription Warrants.
5. In connection with the provisions of Sub-Paragraph 14 above, the Management Board shall be authorised to increase the Company's share capital through the issuance of new Series B ordinary registered shares or subsequent series with a nominal value of PLN 0.1 (ten grosz) each, in an amount not greater than 3.5% (three and a half percent) of the value of the share capital as of the date of the increase and at the same time not greater than 70,000 (seventy thousand) shares and the total nominal value of all the new shares not exceeding PLN 7,000 (seven thousand zloty), by way of one or several share capital increases (authorised capital).
6. The Management Board's authorisation to increase the share capital within the authorised capital shall expire 3 (three) years from the date on which the Company is entered in the Register of Entrepreneurs of the National Court Register.
7. The Company's Management Board may issue New Shares in exchange for contributions in cash or in kind.
8. The New Shares shall be taken up by private subscription.
9. The Management Board, with the exclusion of the Supervisory Board, shall decide on all matters relating to the increase of the share capital within the limits of the authorised capital, in particular the Management Board shall be authorised to:
 - a) determine the issue price of the New Shares,
 - b) fix the dates for the execution of agreements to subscribe for the New Shares,
 - c) determine the designation of subsequent issues of New Shares,
 - d) issue New Shares in exchange for contributions in kind,
 - e) adopt resolutions, submit proposals and perform actions with respect to applying for the admission and introduction of the New Shares to trading on the regulated market,

10. The Management Board may divest existing shareholders of all or part of their preemptive rights in relation to the New Shares and the Subscription Warrants with the consent of the Supervisory Board.
11. Subject to the other provisions of this paragraph, the Company may issue registered securities entitling the holder thereof to subscribe for shares with preemptive rights excluded (Share Subscription Warrants). Paragraphs 7 (2), 7 (3) and Sub-Paragraph 9 (a) shall apply accordingly to the Share Subscription Warrants. It shall be possible to exercise the rights attached to the Share Subscription Warrants until 28 February 2027.

Disposal of shares by a shareholder, joining and preemption rights

§8.

1. Shares shall be transferable and indivisible. They may be issued in collective share certificates.
2. The transfer of registered shares between shareholders shall be carried out without restriction.
3. If an offer to purchase registered shares is made in good faith by a Purchaser to a shareholder, that shareholder shall inform the Management Board in writing of that offer ("Third Party Offer"). The Management Board shall inform the other shareholders holding registered shares of this offer and its contents ("Sale Notice"), based on the information from the shareholder containing:
 - a) the identity of the shareholder,
 - b) the number of registered shares included in the Third Party Offer,
 - c) the intention to sell registered shares, including the number of registered shares the shareholder himself/herself intends to sell,
 - d) the identity of the Purchaser,
 - e) the expected date of completion of the sale of registered shares to the Purchaser,
 - f) the price offered for the sale of registered shares, including the price quoted on a per share basis,
 - g) the conditions for payment of the price.
4. Upon receipt of the Notice of Sale, the remaining shareholders holding registered shares shall within 10 (ten) days submit to the Company and all shareholders holding such shares a statement of their intention to exercise their right to join in the sale of the shares to the Purchaser on the terms and conditions set out in the Third Party Offer and the number of shares to which their intention relates ("Transferable Shares").
5. In respect of all the Transferable Shares, the shareholders holding registered shares have a preemptive right to purchase under the terms of the Third Party Offer,
6. The preemptive right shall be exercised by submitting an appropriate statement to the Management Board (including by email if the shareholder has provided the Company with an address to which notices may be sent) within 10 (ten) days of the delivery to the shareholder of the notice of the intention to dispose of the Shares (the "Preemptive Right Notice"). In the event that more than one eligible shareholder exercises their preemptive right, the Transferable Shares shall be distributed among the eligible shareholders who have filed a notice of exercise of their preemptive right in proportion to the registered shares held by them (the sum of the shares held by all shareholders holding registered shares who have filed a notice of exercise of their preemptive right shall be treated as 100%). Eligible shareholders who have declared their intent to exercise their preemptive right may agree a different proportion for acquisition of the Transferable Shares, provided that they submit a unanimous declaration to the Company's Management Board; if fractions arise, the allocation shall be made by the Management Board.
7. Within 7 (seven) days from the expiry of the deadline for submission of a statement on the exercise of the preemptive right to acquire registered shares, the Management Board shall inform the shareholder disposing of the Transferable Shares of its refusal to consent to the planned disposal and indicate as purchasers the authorised shareholders who have exercised the preemptive right. Within the same period, the Management Board shall also inform the shareholders who have exercised their pre-emptive right.
8. Agreements for the sale of the Transferable Shares shall be executed within 14 (fourteen) days of the date of notification by the Management Board, at the price contained in the Third Party Offer and the payment period specified in the Third Party Offer.
9. Those holders of registered shares who have not exercised their preemptive right shall have the right to demand that their shares be sold to the Purchaser on the terms set out in the Third Party Offer by delivering to the shareholder who received the Third Party Offer a written notice no later than within 10

- (ten) business days specifying the number of the shares remaining of the Transferable Shares that the shareholder concerned intends to sell to the Purchaser ("Notice on Joining").
10. If the Notice on Joining is served on the shareholder and the Third Party Offer does not include all of the shares remaining of the Transferable Shares that all shareholders intend to sell to the Purchaser, then the shareholders wishing to sell shares shall be entitled to sell their shares to the Purchaser in proportion to the number of their shares in relation to the number of all registered shares.
 11. At the request of any shareholder formulated in the Preemptive Right Notice or in the Notice on Joining, the valuation of the shares underlying the price offered by the Purchaser shall be verified by an independent expert appointed by all shareholders interested in the sale of the shares. If the shareholders do not jointly select an independent expert within seven days of the receipt of the last of the Notices on Joining, the Management Board shall, at the request of any of the shareholders interested in the sale, immediately select an independent expert.
 12. Any legal action limiting the shareholders' preemptive rights to acquire the transferable registered shares shall be ineffective both with respect to them and to the Company. In particular, no shareholder shall enter into any agreement or understanding with the Purchaser or incur any obligation which would result in that entity obtaining higher remuneration or better conditions than those set out in the Notification of Sale. The sale of the shares of all interested parties to the Purchaser shall be made at the same time and place and on no less favourable terms, including as regards the price (per share).
 13. The pledgee and the share user may not exercise voting rights.

The Company's Governing Bodies

§ 9

1. The Company's Governing Bodies shall be:
 - 1) the General Meeting;
 - 2) the Supervisory Board;
 - 3) the Management Board.
2. Resolutions of the Company's bodies shall be adopted by a simple majority of votes, subject to the provisions of the Commercial Companies Code and the provisions of the Articles of Association to the contrary.

General Meeting;

§10

1. The General Meeting shall be convened by the Management Board. In the cases specified in the Commercial Companies Code, the General Meeting may be convened by the Supervisory Board or the shareholders.
2. The General Meetings shall be held at the Company's registered office.

§11

1. The Meeting shall be opened by the Chair of the Supervisory Board, and in the absence of the Chair of the Supervisory Board, by the President of the Management Board or a person appointed by the Management Board. After the opening of the Meeting, the Chair of the Meeting shall be elected out of the persons entitled to participate in the General Meeting.
2. The General Meeting shall be attended by members of the Supervisory Board and the Management Board, who shall answer the questions of the General Meeting to the extent necessary to resolve the matters discussed by the General Meeting.
3. Subject to the provisions of the Commercial Companies Code:
 - 1) The General Meeting shall pass resolutions irrespective of the number of shares represented at it.
 - 2) those objecting to resolutions shall be given an opportunity to state concisely the grounds for their objections.
 - 3) shareholder(s) representing at least one-twentieth of the share capital may require that specific items be put on the agenda of the next General Meeting.
 - 4) The General Meeting may order that its proceedings be adjourned. In total, the adjournments may not be longer than 30 (thirty) days. Short breaks in the meeting which do not constitute an

adjournment may be ordered by the Chair in justified cases, but they may not hinder the shareholders from exercising their rights.

- 5) General Meeting resolutions shall be voted on by open ballot.
- 6) The Annual General Meeting shall be convened within six months from the end of each financial year.

§12

In addition to the matters specified in the provisions of the Commercial Companies Code, resolutions of the General Meeting shall:

- 1) determine the operating principles and the remuneration of the members of the Supervisory Board,
- 2) adopt the Rules of Procedure of the General Meeting.

The Supervisory Board

§13

1. The Supervisory Board shall exercise constant supervision over the Company's activities in all areas of its operations.
2. The Supervisory Board shall be composed of at least three (3) members, and in the event of obtaining the status of a public company 5 (five) members, appointed and dismissed by the General Meeting.
3. The Members of the Supervisory Board shall be appointed for a term of office of 5 (five) years. The Members of the Supervisory Board shall be appointed for separate terms of office.
4. As long as the shareholders: Total Fundusz Inwestycyjny Zamknięty with its principal place of business in Warsaw, Piotr Garstecki and Marcin Izydorczak each hold at least 10% (ten per cent) of the shares in the Company's share capital, each of them shall have the right to appoint and dismiss one member of the Supervisory Board.
5. Upon the loss of the power referred to in Paragraph 4 above, the power to appoint and dismiss all members of the Supervisory Board shall be vested in the General Meeting.
6. If within two weeks from a resignation of a member of the Supervisory Board or a dismissal of a member of the Supervisory Board or an expiry of the mandate of a member of the Supervisory Board, the minimum composition of the Supervisory Board specified in section 2 is not appointed, then the vacancies on the Supervisory Board shall be temporarily filled by a resolution of the remaining members of the Supervisory Board. The temporary members of the Supervisory Board shall perform their duties in the Supervisory Board until the appointment of the missing members of the Supervisory Board.
7. Together with the financial statements submitted by the Management Board, the Supervisory Board shall prepare and present to the Annual General Meeting:
 - 1) a brief assessment of the Company's situation, including an evaluation of the Company's internal control system and the system for managing the risks which are substantial to the Company,
 - 2) a report on the activities of the Supervisory Board for the preceding financial year.

§14

The competence of the Supervisory Board includes the matters provided for by the Commercial Companies Code and those specified below, in particular:

- 1) assessment of the Management Board's report on the Company's activities and the financial statements for the preceding financial year in terms of their compliance with the books, documents and facts (this also applies to the consolidated financial statements, if any),
- 2) evaluation of the Management Board's proposals on the distribution of profit or coverage of loss,
- 3) delivery to the General Meeting of an annual written report on the results of the activities referred to in (1) and (2);
- 4) appointment of a statutory auditor to audit the financial statements,
- 5) approval of the Company's multi-annual strategic plans drawn up by the Management Board,
- 6) approval of annual investment, financial and budgetary plans drawn up by the Management Board,
- 7) adoption of the Rules of Procedure of the Supervisory Board in detail,
- 8) adoption of the Rules of Procedure of the Company's Management Board,
- 9) expressing its opinion on the Company's organisational regulations,

- 10) approval of loyalty and incentive schemes for employees and associates of the Company, based on possible dilution of the Company's capital,
- 11) formulation of the principles for remuneration and the amount of remuneration for members of the Management Board and the principles for execution and approval of all contracts with members of the Management Board,
- 12) delegating members of the Supervisory Board to temporarily perform the duties of those members of the Management Board unable to perform their duties,
- 13) expressing an opinion on an ongoing basis on the activities of the Management Board in relation to its subsidiaries, following the presentation by the Management Board of its report on the activities of those companies, at the Board's request.
- 14) giving its consent to:
 - a) creation of Company branches,
 - b) establishment of subsidiaries,
 - c) issuing bills of exchange, taking out loans,
 - d) providing financial guarantees or sureties, subject to (e) below,
 - e) granting financial guarantees or sureties and loans to subsidiaries of a total value exceeding PLN 1,000,000 (one million zloty) in a calendar year,
 - f) acquisition or disposal of real estate, perpetual usufruct or a share in real estate, regardless of the value of such estate,
 - g) payment by the Company to its shareholders of an advance on future dividends,
 - h) acquisition or disposal by the Company of shares in other companies.

§15

1. The meetings of the Supervisory Board shall be convened by the Chair of the Board, or in the absence of the Chair, by another Member of the Supervisory Board.
2. The Supervisory Board shall meet at least once every quarter.
3. It shall be the duty of each member of the Supervisory Board to attend the Supervisory Board meetings. Each member of the Supervisory Board shall give the reasons for his/her absence from the Board meeting.
4. The Supervisory Board meetings shall be chaired by its Chair, or in his/her absence by another Member of the Supervisory Board.
5. The Chair of the Supervisory Board shall be appointed by the members of the Supervisory Board from among themselves at the first meeting of a new Supervisory Board. The Supervisory Board may dismiss the Chair at any time.
6. Statements addressed to the Supervisory Board between meetings shall be made to the Chair of the Board.
7. Resolutions of the Supervisory Board may be passed if at least a half of its members are present at the meeting and all its members have been invited at least 7 working days before the planned meeting. Members of the Supervisory Board may participate in adopting resolutions of the Supervisory Board by casting their votes in writing through another member of the Supervisory Board, except for matters placed on the agenda at the meeting of the Supervisory Board. Detailed principles for convening and holding meetings are defined in the Rules of Procedure of the Supervisory Board adopted by the Board.
8. The Supervisory Board resolutions shall be recorded in Meeting minutes.
9. Subject to the provisions of the Commercial Companies Code, the Supervisory Board shall adopt resolutions by open ballot, at meetings, in writing (currenda) or by means of direct remote communication. The detailed voting procedure in these cases shall be set out in the Rules of Procedure of the Supervisory Board.
10. A secret ballot shall be ordered at the request of a member of the Supervisory Board and in personal matters. If a secret ballot is ordered, the provisions of the first sentence of paragraph 9 shall not apply.
11. Resolutions of the Supervisory Board shall be adopted by a simple majority of the Supervisory Board members participating in the adoption of the resolution. In the event of an equality of votes, the Chair of the Supervisory Board shall have the casting vote.

§16

1. Members of the Supervisory Board shall exercise their rights and perform their duties in person.

2. The members of the Supervisory Board are entitled to remuneration in the amount determined by the General Meeting.

§17

1. The Supervisory Board may create internal committees. The detailed scope of rights and obligations and the procedure of work of the committees created by the Supervisory Board shall be laid down in the rules of procedure of the Supervisory Board.
2. In the event of obtaining the status of a public company, an Audit Committee shall be established within the Supervisory Board, consisting of 3 (three) members, elected from among the members of the Supervisory Board, appointed and dismissed by way of a resolution of the Supervisory Board. A Supervisory Board constituted of 5 (five) members may adopt a resolution to delegate the tasks of the Audit Committee to the Supervisory Board in corpore. In such a case, the provisions of the Articles of Association and internal regulations regarding the tasks and functioning of the Committee shall apply to the Supervisory Board accordingly. At least one member of the Committee shall have a qualification in accounting or auditing.
3. The Audit Committee shall issue opinions and recommendations to the Supervisory Board on all Company matters of a financial nature and relating to internal control and risk management, but the opinions or recommendations submitted by the Audit Committee are not binding for the Supervisory Board.
4. Within the scope of its powers, the Supervisory Board may consult the Audit Committee on all matters relating to the Company's finances, internal control and risk management.

The Management Board

§18

1. All matters relating to the management of the Company's affairs not reserved by law or the provisions of these Articles of Association for the General Meeting or the Supervisory Board shall be the responsibility of the Management Board.
2. The Management Board shall be responsible for drawing up, introducing and implementing loyalty and incentive programmes for employees and associates of the Company, after the Supervisory Board has given its opinion on the framework and general principles.
3. The Company's Management Board consists of two to three persons appointed and dismissed by Supervisory Board resolution for a term of office lasting 5 (five) years. The resolution shall indicate the function of a given person in the Management Board. Members of the Management Board shall be appointed for separate terms of office.
4. Any member of the Management Board may be dismissed or suspended by the Supervisory Board.
5. The same person may be elected as a member of the Management Board more than once.
6. The Management Board, in the case of a multi-member Management Board, shall consist of the President of the Management Board and the Vice-Presidents of the Management Board.
7. The Company shall be represented by two Members of the Management Board acting jointly or by one Member of the Management Board together with a power of procurator holder.
8. A member of the Management Board may not, without the consent of the Supervisory Board granted by resolution, engage in competitive business.

§19

1. The Management Board may adopt its own rules of procedure, specifying its internal organisation and the manner in which it is to perform its duties. This provision shall not apply to a one-person Management Board.
2. The meetings shall be convened by the President of the Management Board on his/her own initiative or at the request of any member of the Management Board. If the President fails to convene a meeting within 7 (seven) days of the request, the meeting of the Management Board may be convened by the petitioners.
3. Resolutions may be adopted if all members of the Management Board have been notified in writing of the date of the meeting (including by email, provided that the notifier has received a confirmation of receipt from the addressee) at least 3 days before the planned date of the meeting.

4. Resolutions of the Management Board shall be adopted by a simple majority of votes of the Management Board Members participating in the adoption of the resolution. In the case of a tie, the President of the Management Board shall have the casting vote.

§20

1. Contracts with members of the Management Board shall be executed on behalf of the Company by the Chair of the Supervisory Board. The Supervisory Board shall determine the detailed terms of such agreements. The same procedure shall also apply to other legal transactions between the Company and members of the Management Board.
2. The Chair of the Supervisory Board represents the Company in disputes with members of the Management Board.

Company management

§21

The Company's financial year is the calendar year. The Company's first financial year shall end on 31 December 2017.

Dissolution of the Company

§22

1. The dissolution of the Company shall take place after its liquidation.
2. The liquidators of the Company shall be the members of the Management Board, unless the General Meeting, by resolution, shall decide otherwise.
3. The assets of the Company remaining after satisfying or securing the creditors shall be distributed among the shareholders evenly to the number of shares held by them. The registered shareholders shall have priority where the Company's assets constituting copyright or industrial property rights shall be used to satisfy the Company's liabilities.

Appendix 3 - Definitions and explanations of abbreviations

Series F Shares	231,540 series F ordinary bearer shares with a nominal value of PLN 0.10 each, arising from the adoption on 10 December 2019 by the Extraordinary General Meeting of Resolution No. 3 on increasing the Company's share capital through the issuance of series F shares by private subscription with complete exclusion of the preemptive rights of existing shareholders, dematerialisation and introduction to trading in the Alternative Trading System on the NewConnect market operated by the Warsaw Stock Exchange, and amendment to the Articles of Association.
Alternative Trading System, ATS, NewConnect	An alternative trading system referred to in Article 3 (2) of the Act on Trading in Financial Instruments, organised by the Warsaw Stock Exchange on the NewConnect market
Authorised Advisor	Mercurius Financial Advisors Spółka z ograniczoną odpowiedzialnością spółka komandytowa with its principal place of business in Warsaw
Bacteromic, Bacteromic Sp. z o.o.	Bacteromic Limited liability company with registered office with its principal place of business in Warsaw.
Curiosity Diagnostic, Curiosity Diagnostics Sp. z o.o.	Curiosity Diagnostics Limited liability company with its principle place of business in Warsaw
Information document	Information document - simplified - prepared in accordance with the requirements specified in Appendix 1 to the Alternative Trading System Rules adopted as Resolution No. 147/2007 of the Warsaw Stock Exchange Management Board dated 1 March 2007 (as amended)
EUR	Monetary unit of the European Union
Stock Exchange, WSE, ATS Organizer, Alternative System Organizer (Giełda, GPW, Organizator ASO, Organizator Alternatywnego Systemu)	Warsaw Stock Exchange, with its principal place of business in Warsaw (Giełda Papierów Wartościowych w Warszawie S.A z siedzibą w Warszawie)
NDS, Depository (KDPW, Depozyt)	The National Depository for Securities (KDPW S.A.) with its principal place of business in Warsaw
Commercial Companies Code, CCC (Kodeks Spółek Handlowych, KSH)	Act of 15 September 1997 Commercial Companies Code (consolidated text of 22 February 2019, Journal of Laws 2019, item 505, as amended).
KNF, Commission	Financial Supervision Authority
Extraordinary General Meeting	Extraordinary General Meeting of Scope Fluidics S.A.
NCBiR	National Centre for Research and Development
The Supervisory Board	Supervisory Board of Scope Fluidics S.A.
ATS Regulations	Rules of the Alternative Trading System, adopted by Resolution No. 70/2020
MAR Regulation	Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC
Court, Registry Court	District Court in Warsaw, XIII Commercial Division of the National Court Register
Scope Fluidics, Scope Fluidics S.A, Issuer, Company	Scope Fluidics Spółka Akcyjna with its principal place of business in Warsaw

Scope Fluidics Sp. z o.o.	Scope Fluidics Spółka z ograniczoną odpowiedzialnością, with its principal place of business in Warsaw, legal predecessor of the Issuer
TOTAL FIZ	TOTAL Fundusz Inwestycyjny Zamknięty with its principal place of business in Warsaw
EU	European Union
Act on Financial Instruments Circulation;	Act of 29 July 2005 on trading in financial instruments (consolidated text of 9 November 2018, Journal of Laws of 2018, item 2286)
Act on Public Offering	Act of 29 July 2005 on public offering and the conditions for introducing financial instruments to the organised trading system and on public companies (consolidated text of 22 February 2019, Journal of Laws 2019, item 623)
Accounting Act	Act of 29 September 1994 on accounting (consolidated text of 17 January 2019, Journal of Laws 2019, item 351)
The Management Board	Management Board of Scope Fluidics S.A.
General Meeting, General Assembly	General Meeting of Scope Fluidics S.A.